NO800620L - PROCEDURE FOR THE PREPARATION OF PROLINIC AND PIPE CARBIC ACID DERIVATIVES. - Google Patents
PROCEDURE FOR THE PREPARATION OF PROLINIC AND PIPE CARBIC ACID DERIVATIVES.Info
- Publication number
- NO800620L NO800620L NO800620A NO800620A NO800620L NO 800620 L NO800620 L NO 800620L NO 800620 A NO800620 A NO 800620A NO 800620 A NO800620 A NO 800620A NO 800620 L NO800620 L NO 800620L
- Authority
- NO
- Norway
- Prior art keywords
- proline
- hydrogen
- oxo
- oxopropyl
- lower alkyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 42
- 238000002360 preparation method Methods 0.000 title claims description 9
- NIDNOXCRFUCAKQ-UMRXKNAASA-N (1s,2r,3s,4r)-bicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid Chemical class C1[C@H]2C=C[C@@H]1[C@H](C(=O)O)[C@@H]2C(O)=O NIDNOXCRFUCAKQ-UMRXKNAASA-N 0.000 title 1
- 239000001257 hydrogen Substances 0.000 claims description 34
- 229910052739 hydrogen Inorganic materials 0.000 claims description 34
- 125000000217 alkyl group Chemical group 0.000 claims description 24
- -1 keto-substituted proline Chemical class 0.000 claims description 23
- 239000002253 acid Substances 0.000 claims description 19
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 15
- 125000004432 carbon atom Chemical group C* 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 15
- 125000006239 protecting group Chemical group 0.000 claims description 14
- 150000002431 hydrogen Chemical class 0.000 claims description 13
- 239000007858 starting material Substances 0.000 claims description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical class [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 6
- 229910052740 iodine Inorganic materials 0.000 claims description 6
- 239000011630 iodine Substances 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- 125000004414 alkyl thio group Chemical group 0.000 claims description 4
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 3
- 125000000468 ketone group Chemical group 0.000 claims description 3
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims description 3
- 125000001589 carboacyl group Chemical group 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 81
- 239000000047 product Substances 0.000 description 37
- 239000000243 solution Substances 0.000 description 37
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 32
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 23
- 150000001875 compounds Chemical class 0.000 description 23
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 22
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 20
- 239000002904 solvent Substances 0.000 description 17
- 229960002429 proline Drugs 0.000 description 16
- 238000001816 cooling Methods 0.000 description 14
- 239000010410 layer Substances 0.000 description 14
- 239000007787 solid Substances 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 229910021529 ammonia Inorganic materials 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 229910052786 argon Inorganic materials 0.000 description 10
- UNUDUTMFKRKUIJ-UHFFFAOYSA-N 4-oxopentanethioyl chloride Chemical compound CC(=O)CCC(Cl)=S UNUDUTMFKRKUIJ-UHFFFAOYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 239000008346 aqueous phase Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N methyl pentane Natural products CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
- 239000012044 organic layer Substances 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 6
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 6
- HFXAFXVXPMUQCQ-BYPYZUCNSA-N 4-oxo-L-proline Chemical compound OC(=O)[C@@H]1CC(=O)CN1 HFXAFXVXPMUQCQ-BYPYZUCNSA-N 0.000 description 5
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 230000008020 evaporation Effects 0.000 description 5
- HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 5
- RPLLCMZOIFOBIF-NSHDSACASA-N (2s)-4-oxo-1-phenylmethoxycarbonylpyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CC(=O)CN1C(=O)OCC1=CC=CC=C1 RPLLCMZOIFOBIF-NSHDSACASA-N 0.000 description 4
- SFSROLZHCPCODJ-WCCKRBBISA-N (2s)-4-oxopyrrolidine-2-carboxylic acid;hydrobromide Chemical compound Br.OC(=O)[C@@H]1CC(=O)CN1 SFSROLZHCPCODJ-WCCKRBBISA-N 0.000 description 4
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 4
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 4
- 102000005862 Angiotensin II Human genes 0.000 description 4
- 101800000733 Angiotensin-2 Proteins 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 4
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 229950006323 angiotensin ii Drugs 0.000 description 4
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 239000002934 diuretic Substances 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- WWVCWLBEARZMAH-DTIOYNMSSA-N (2s)-4-hydroxy-1-phenylmethoxycarbonylpyrrolidine-2-carboxylic acid Chemical compound C1C(O)C[C@@H](C(O)=O)N1C(=O)OCC1=CC=CC=C1 WWVCWLBEARZMAH-DTIOYNMSSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 101800000734 Angiotensin-1 Proteins 0.000 description 3
- 102400000344 Angiotensin-1 Human genes 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000000908 ammonium hydroxide Substances 0.000 description 3
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 3
- 239000012300 argon atmosphere Substances 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 235000015497 potassium bicarbonate Nutrition 0.000 description 3
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 3
- 239000011736 potassium bicarbonate Substances 0.000 description 3
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- FKUTWIRYUABSKQ-LURJTMIESA-N (2s)-4-oxo-1-(3-sulfanylpropanoyl)pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CC(=O)CN1C(=O)CCS FKUTWIRYUABSKQ-LURJTMIESA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- GVCARDRZNAPXPT-UHFFFAOYSA-N 2-methylsulfanylprop-2-enoic acid Chemical compound CSC(=C)C(O)=O GVCARDRZNAPXPT-UHFFFAOYSA-N 0.000 description 2
- AZSXBSYVGBDHTA-UHFFFAOYSA-N 3-acetylsulfanyl-2-methylsulfanylpropanoic acid Chemical compound CSC(C(O)=O)CSC(C)=O AZSXBSYVGBDHTA-UHFFFAOYSA-N 0.000 description 2
- 102000004881 Angiotensinogen Human genes 0.000 description 2
- 108090001067 Angiotensinogen Proteins 0.000 description 2
- 108010064733 Angiotensins Proteins 0.000 description 2
- 102000015427 Angiotensins Human genes 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 2
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 108090000783 Renin Proteins 0.000 description 2
- FHKPLLOSJHHKNU-INIZCTEOSA-N [(3S)-3-[8-(1-ethyl-5-methylpyrazol-4-yl)-9-methylpurin-6-yl]oxypyrrolidin-1-yl]-(oxan-4-yl)methanone Chemical compound C(C)N1N=CC(=C1C)C=1N(C2=NC=NC(=C2N=1)O[C@@H]1CN(CC1)C(=O)C1CCOCC1)C FHKPLLOSJHHKNU-INIZCTEOSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 2
- 238000005915 ammonolysis reaction Methods 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 125000001891 dimethoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- DUYAAUVXQSMXQP-UHFFFAOYSA-N ethanethioic S-acid Chemical compound CC(S)=O DUYAAUVXQSMXQP-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- TZBHHPYGZROULI-UHFFFAOYSA-N s-(3-chloro-2-methylsulfanyl-3-oxopropyl) ethanethioate Chemical compound CSC(C(Cl)=O)CSC(C)=O TZBHHPYGZROULI-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910052717 sulfur Chemical group 0.000 description 2
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 2
- HGJZUVHTFSPDPZ-MQWKRIRWSA-N (2s)-4,4-dimethoxy-1-(2-methyl-3-sulfanylpropanoyl)pyrrolidine-2-carboxylic acid Chemical compound COC1(OC)C[C@@H](C(O)=O)N(C(=O)C(C)CS)C1 HGJZUVHTFSPDPZ-MQWKRIRWSA-N 0.000 description 1
- PTDVPWWJRCOIIO-UHFFFAOYSA-N (4-methoxyphenyl)methanethiol Chemical compound COC1=CC=C(CS)C=C1 PTDVPWWJRCOIIO-UHFFFAOYSA-N 0.000 description 1
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
- JIVPVXMEBJLZRO-CQSZACIVSA-N 2-chloro-5-[(1r)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC([C@@]2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-CQSZACIVSA-N 0.000 description 1
- GZGBVRKSXMCBPV-UHFFFAOYSA-N 3,3,3-trifluoro-2-[(4-methoxyphenyl)methylsulfanylmethyl]propanoic acid Chemical compound COC1=CC=C(CSCC(C(O)=O)C(F)(F)F)C=C1 GZGBVRKSXMCBPV-UHFFFAOYSA-N 0.000 description 1
- PSGUKONEIBCWQN-UHFFFAOYSA-N 3,3,3-trifluoro-2-[(4-methoxyphenyl)methylsulfanylmethyl]propanoyl chloride Chemical compound COC1=CC=C(CSCC(C(Cl)=O)C(F)(F)F)C=C1 PSGUKONEIBCWQN-UHFFFAOYSA-N 0.000 description 1
- MWOOKDULMBMMPN-UHFFFAOYSA-N 3-(2-ethyl-1,2-oxazol-2-ium-5-yl)benzenesulfonate Chemical compound O1[N+](CC)=CC=C1C1=CC=CC(S([O-])(=O)=O)=C1 MWOOKDULMBMMPN-UHFFFAOYSA-N 0.000 description 1
- PSPOEQSCJVBCDR-UHFFFAOYSA-N 3-oxobutanethioyl chloride Chemical compound CC(=O)CC(Cl)=S PSPOEQSCJVBCDR-UHFFFAOYSA-N 0.000 description 1
- UYLDJKGHDNEMOP-UHFFFAOYSA-N 5-oxohexanethioyl chloride Chemical compound CC(=O)CCCC(Cl)=S UYLDJKGHDNEMOP-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- CYLWJCABXYDINA-UHFFFAOYSA-N Polythiazide Polymers ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CSCC(F)(F)F)NC2=C1 CYLWJCABXYDINA-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 102000005686 Serum Globulins Human genes 0.000 description 1
- 108010045362 Serum Globulins Proteins 0.000 description 1
- 239000004133 Sodium thiosulphate Substances 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
- 229960002576 amiloride Drugs 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 150000003974 aralkylamines Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- NDTSRXAMMQDVSW-UHFFFAOYSA-N benzthiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1N=C2CSCC1=CC=CC=C1 NDTSRXAMMQDVSW-UHFFFAOYSA-N 0.000 description 1
- 229960001541 benzthiazide Drugs 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 description 1
- 229960004064 bumetanide Drugs 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 229960002155 chlorothiazide Drugs 0.000 description 1
- 229960001523 chlortalidone Drugs 0.000 description 1
- KRVSOGSZCMJSLX-UHFFFAOYSA-L chromic acid Substances O[Cr](O)(=O)=O KRVSOGSZCMJSLX-UHFFFAOYSA-L 0.000 description 1
- 150000001844 chromium Chemical class 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 150000003946 cyclohexylamines Chemical class 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 description 1
- 229960003199 etacrynic acid Drugs 0.000 description 1
- MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- RGUQWGXAYZNLMI-UHFFFAOYSA-N flumethiazide Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O RGUQWGXAYZNLMI-UHFFFAOYSA-N 0.000 description 1
- 229960003028 flumethiazide Drugs 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- AWJWCTOOIBYHON-UHFFFAOYSA-N furo[3,4-b]pyrazine-5,7-dione Chemical compound C1=CN=C2C(=O)OC(=O)C2=N1 AWJWCTOOIBYHON-UHFFFAOYSA-N 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- AWJZTPWDQYFQPQ-UHFFFAOYSA-N methyl 2-chloroprop-2-enoate Chemical compound COC(=O)C(Cl)=C AWJZTPWDQYFQPQ-UHFFFAOYSA-N 0.000 description 1
- QCGQAWBHALUDCD-UHFFFAOYSA-N methyl 2-methylsulfanylprop-2-enoate Chemical compound COC(=O)C(=C)SC QCGQAWBHALUDCD-UHFFFAOYSA-N 0.000 description 1
- ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229960005483 polythiazide Drugs 0.000 description 1
- 229920000046 polythiazide Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- SITTWQPUINJZTD-UHFFFAOYSA-N s-(3-chloro-2,2-dimethyl-3-oxopropyl) ethanethioate Chemical compound CC(=O)SCC(C)(C)C(Cl)=O SITTWQPUINJZTD-UHFFFAOYSA-N 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- AGHANLSBXUWXTB-UHFFFAOYSA-N tienilic acid Chemical compound ClC1=C(Cl)C(OCC(=O)O)=CC=C1C(=O)C1=CC=CS1 AGHANLSBXUWXTB-UHFFFAOYSA-N 0.000 description 1
- 229960000356 tienilic acid Drugs 0.000 description 1
- 229960001288 triamterene Drugs 0.000 description 1
- 229960004813 trichlormethiazide Drugs 0.000 description 1
- LMJSLTNSBFUCMU-UHFFFAOYSA-N trichlormethiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC(C(Cl)Cl)NS2(=O)=O LMJSLTNSBFUCMU-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Steroid Compounds (AREA)
- Pyrane Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
Denne oppfinnelse angår fremstilling av keto-derivater av merkaptoacylprolin og -pipekolsyre med formel I og saltene derav This invention relates to the preparation of keto derivatives of mercaptoacylproline and -pipecolic acid with formula I and the salts thereof
(I) (IN)
R og R_ er uavhengig av hverandre valgt fra hydrogen og lavere alkyl, forutsatt at er lavere alkyl bare når også er lavere alkyl. R and R_ are independently selected from hydrogen and lower alkyl, provided that is lower alkyl only when is also lower alkyl.
R^ og R^er uavhengig av hverandre valgt fra hydrogen, lavere alkyl, lavere alkyltio, -(CI^) -SH og halogen-substituert lavere alkyl.(R^ and R^ are independently selected from hydrogen, lower alkyl, lower alkylthio, -(CI^) -SH and halogen-substituted lower alkyl.
R^er hydrogen, en beskyttelsesgruppe som kan fjernes hydrolytisk, en beskyttelsesgruppe som kan fjernes kjemisk, eller når R., og R-, er forskjellig fra -(CH„) -SH, en sulfid-1^3 2 n gruppe med formelen R^ is hydrogen, a hydrolytically removable protecting group, a chemically removable protecting group, or when R., and R-, is different from -(CH„) -SH, a sulfide-1^3 2 n group of the formula
m er 0', 1 eller 2. m is 0', 1 or 2.
n er 1, 2 eller 3.- n is 1, 2 or 3.-
p og q er hver 1 eller 2, forutsatt at begge ikke er 2. , s ' Stjernen i den ovenstående formel betegner et asymmetri-senter i ringen. For prolins vedkommende, dvs. p og q er. begge 1, er dette senter i L-konfigurasjon. For pipekolsyres vedkommende, dvs. én av p og q er 2, er dette senter i D,L-eller L-konfigurasjon. p and q are each 1 or 2, provided both are not 2. , s ' The star in the above formula denotes an asymmetry center in the ring. In the case of proline, i.e. p and q are. both 1, this is center in L configuration. In the case of pipecholic acid, i.e. one of p and q is 2, this center is in D, L or L configuration.
Asymmetrisentere kan også være til stede i merkaptoacyl- sidekjeden, avhengig av definisjonen av R^, R ? og R^. Produktene kan således eksistere i stereoisomere former eller, som racemiske blandinger derav. Alle disse kan fremstilles i henhold til oppfinnelsen. Syntesen beskrevet nedenfor kan utføres under anvendelse av racematet eller en av enantiomerene som utgangsmaterialer. Når det racemiske utgangsmateriale anvendes ved syntesen, kan stereoisomerene erholdt i sluttproduktet, separeres ved vanlig kromatografisk eller fraksjonert krystallisasjon. Hvis det er et asymmetri-senter i merkaptoacy1-sidekjeden, er det fortrinnsvis i D-konfigurasjon. Centers of asymmetry may also be present in the mercaptoacyl side chain, depending on the definition of R^, R ? and R^. The products can thus exist in stereoisomeric forms or, as racemic mixtures thereof. All of these can be produced according to the invention. The synthesis described below can be carried out using the racemate or one of the enantiomers as starting materials. When the racemic starting material is used in the synthesis, the stereoisomers obtained in the final product can be separated by ordinary chromatographic or fractional crystallization. If there is an asymmetry center in the mercaptoacy1 side chain, it is preferably in the D configuration.
Denne oppfinnelse angår generelt fremstilling av merkapto-acy 1-derivatene av prolin og pipekolsyre med formel I ovenfor og salter derav, som er egnet som anti-hypertensive midler. This invention generally relates to the preparation of the mercapto-acyl derivatives of proline and pipecolic acid of formula I above and salts thereof, which are suitable as anti-hypertensive agents.
Betegnelsen "lavere alkyl" som anvendt ved definisjon av symbolene R, R^, R2og R^, er lineære eller forgrenede hydrokarbonradikaler med opptil 7 karbonatomer, f.eks. metyl, etyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl', isopentyl, osv. De foretrukne lavere alkylgrupper inneholder opptil 4 karbonatomer, idet metyl og etyl er særlig foretrukket. Betegnelsene "lavere alkoksy" og "lavere alkyltio" betegner tilsvarende slike lavere alkylgrupper bundet til et oksygen- eller svovelatom. The term "lower alkyl" as used in defining the symbols R, R₂, R₂ and R₂ are linear or branched hydrocarbon radicals of up to 7 carbon atoms, e.g. methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl', isopentyl, etc. The preferred lower alkyl groups contain up to 4 carbon atoms, methyl and ethyl being particularly preferred. The terms "lower alkoxy" and "lower alkylthio" denote correspondingly such lower alkyl groups bound to an oxygen or sulfur atom.
Betegnelsen "halogen-substituert lavere alkyl" betegner slike lavere alkylgrupper beskrevet ovenfor hvor ett eller flere av hydrogenatomene er erstattet med klor-, brom- eller fluor-grupper, så som tri fluormety1, pentafluorety1, 2,2,2-triklorety1, klormetyl, brommetyl osv. The term "halogen-substituted lower alkyl" denotes such lower alkyl groups described above where one or more of the hydrogen atoms are replaced by chlorine, bromine or fluorine groups, such as trifluoromethyl, pentafluoroethyl, 2,2,2-trichloroethyl, chloromethyl, bromomethyl etc.
Betegnelsen "beskyttelsesgruppe som kan fjernes hydrolytisk" som anvendes ved definisjonen av R^, betegner en gruppe som kan fjernes ved vanlig hydrolyse eller ammonolyse. Acylgrupper med formelen R^-CO- er egnet for dette formål, hvor<*>R^ kan være lavere alkyl med 1 til 7 karbonatomer, ;lavere alkyl substituert med én eller flere klor-, brom eller fluor-grupper, - (CH2)^-cykloalkyl hvor betegnelsen "cykloalkyl" betegner mettede ringer med 3 til 7 karbonatomer, fortrinnsvis eykloheksyl, en arylgruppe så som ; en heterogruppe så som eller ; hvor r er 0, 1, 2 eller 3; ;RD, er hydrogen, lavere alkyl med 1 til 4 karbonatomer, særlig metyl, lavere alkoksy med 1 til 4 karbonatomer, særlig metoksy, lavere alkyltio med 1 til 4 karbonatomer, særlig metyltid, klor, brom, fluor, tri fluormety1 eller hydroksy; ;og X er oksygen eller svovel. Foretrukne grupper er de lavere alkanoylgrupper med opptil 4 karbonatomer, særlig acetyl, og benzoyl. ;Betegnelsen "beskyttelsesgruppe som kan fjernes kjemisk" som er anvendt ved definisjonen av R^, betegner slike grupper som p-metoksy., p-metoksybenzylkarbony1, trityl, t-butoksy-karbonyl, osv. Disse grupper kan fjernes efter fullførelse av acyleringsreaksjonen, på forskjellige måter så som ved behandling med tri fluoreddiksyre og anisol. ;Foretrukne forbindelser med formel I er det L-prolin-inneholdende derivat, dvs. p og q er begge 1, og R er hydrogen. ;Når det gjelder merkaptoacy1-sidekjeden, er foretrukne sluttprodukter de forbindelser hvor R^er hydrogen; m er 0 eller 1; er hydrogen; og R^og R ? er begge lavere alkyl med 1 til 4 karbonatomer, særlig begge metyl, eller R^ er hydrogen og R^ er hydrogen, lavere alkyl med 1 til 4 karbonatomer, særlig metyl, trifluormetyl, metyltio eller merkaptomety1. Også foretrukket som både mellomprodukter og som sluttprodukter er de ovenstående sidekjeder hvor R^er lavere alkanoyl med 1 til 4 karbonatomer, særlig acetyl, eller benzoyl. ;Særlig foretrukket som sluttprodukter er forbindelsene med formel I med merkaptoacy1-sidekjeden hvor R^er hydrogen; m er 1; R^ og R^er hydrogen; R2er metyl eller hydrogen; og når R2er metyl, er det asymmetriske karbonatom som R2er festet til, i D-konfigurasjon. ;Forbindelsene med formel I fremstilles ved at en keto-substituert prolin eller pipekolsyre med formelen ;(II) ; ; kobles med en syre eller dens. kjemiske ekvivalent med formelen • ;(III) ; hvor ; er hydrogen eller en beskyttelsesgruppe som kan ;fjernes hydrolytisk eller kjemisk, for å danne produktet med formelen ;(IV) ; ; Denne omsetning kan utføres i nærvær av et koblingsmiddel så som dicykloheksylkarbodiimid eller.lignende, eller syren kan aktiveres ved dannelse av dens blandede anhydrid, symmetriske anhydrid, syrehalogenid, aktive ester eller ved anvendelse av Woodward reagens K, N-etoksykarbony1-2-etoksy-1,2-dihydrokinolin eller lignende. For en oversikt over acyleringsmetoder, kan det henvises til Methoden der Organischen Chemie (Houben-Weyl), vol. XV, del II, s. 1 og videre (1974). Fortrinnsvis omsettes syrehalogenidet, særlig syrekloridet, med formel III med syren med formel II. ;Hvis prolin- eller pipekolsyrederivatet med formel II omsettes i esterform, kan det resulterende esterprodukt omdannes- til den frie syre, dvs. R er hydrogen, på vanlig måte. Hvis f.eks. R er etyl, kan denne beskyttende estergruppe fjernes ved forsepning. ;Produktet med formel IV blir fortrinnsvis isolert og renset ved krystallisasjon, f.eks. ved å danne dicykloheksyl-aminsaltet og derefter omdanne saltet til den frie syreform-ved behandling med en vandig oppløsning av en syre, så som kalium-hydrogensulfat. ;Produktet med formel IV som inneholder acylgruppen R^-CO-kan omdannes til produktene med formel I hvor R^er hydrogen, ved vanlig hydrolyse eller ved ammonolyse. ;Produktene med formel I jivor R^og R^er forskjellig fra -(CH„) -SH og R, er 2 n 4 ; ; erholdes ved at et produkt med formel I hvor R^er hydrogen, oksyderes direkte méd jod. ;Estrene med formel I hvor R er lavere alkyl kan erholdes fra karboksylsyreforbindelsene, dvs. hvor R er hydrogen, ved vanlige forestringsmetoder, f.eks. ved forestring med et diazoalkan så som diazometan, et. l-alkyl-3-p-tolyltriazen, så som 1-n-buty1-3-p-tolyltriazen, eller lignende. ;Forbindelsene med formel I kan også fremstilles ved fjernelse av beskyttelsesgruppe(r) i henhold til vanlige metoder fra et keto-substituert prolin- eller pipekolsyreprodukt med formel I som har keto-funksjonen beskyttet med de vanlige beskyttelsesgrupper som f.eks. en beskyttende' ketalgruppe, f.eks. et dialkoksyketal som f.eks. ;(V) ; ; fra hvilken beskyttelsesgruppene kan fjernes ved hydrolyse, f.eks. med en vandig oppløsning av saltsyre ved romtemperatur. ;Forbindelsene med formel V kan fremstilles ved å starte med et N-karbobenzyloksy-ketosubstituert prolin- eller., pipekolsyrederivat med formel II, som derefter behandles med metanol i nærvær av trimety1-ortoformiat og konsentrert svovelsyre, og den N-beskyttende gruppe fjernes derefter ved hydrogenolyse i nærvær av en palladium-kull-katalysator for å danne dimetoksy-mellomproduktet med formelen ;(VI) ; ; Mellomproduktet med .formel VI kobles derefter med en syre eller dens kjemiske ekvivalent med formel III, for å danne dimetoksy-forbindelsene med formel V. ;Det skal også henvises til de følgende publikasjoner som gir ytterligere illustrerende opplysninger med hensyn til frem-stillingen av utgangsmaterialer og mellomprodukter: US-patenter 4.046.889, 4.105.776, 4.154.935 og 4.116.962; Can. J. Biochem.&physiol. _3_Z'583-587 (1959); JACS 79.'s. 185-192 (1957); JACS 79, s. 192-197, (1957); Bull. Soc. Chem., 1965(8), s. 2253-2259; og Aus. J. Chem. 20, s. 1493-1509 (1967). ;De her illustrerte fremgangsmåter kan anvendes som generelle metoder for syntese av forbindelsene og separering av isomerer som kan anvendes ved fremgangsmåten ifølge oppfinnelsen. Ytterligere illustrerende detaljer er vist i eksemplene som ;også tjener som modell for fremstilling av andre forbindelser fra samme gruppe. ;De nye forbindelser danner basiske salter med en rekke uorganiske eller organiske baser. Det saltdannende ion avledet fra slike baser kan være metallioner, f.eks. aluminium, alkalimetallioner, så som natrium eller kalium, jordalkali-metallioner så som kalsium eller magnesium, eller et aminsalt-ion, hvorav en.rekke er kjent for dette formål, f.eks. aralkyl-aminer så som dibenzylamin, N,N-dibenzyletylendiamin, lavere alkyl-aminer så som metylamin, 't-butylamin,. prokain, lavere alkyl-piperidiner så som N-etylpiperidin, cykloalkylaminer så som cykloheksylamin eller dicykloheksylamin, 1-adamantanamin, benzatan eller salter avledet fra aminosyrer så som arginin, lysin eller lignende. De fysiologisk godtagbare salter så som natrium- eller kaliumsaltene kan anvendes medisinsk som beskrevet nedenfor, og foretrekkes. Disse og andre saltér som ikke nødvendigvis er fysiologisk godtagbare, er nyttige for isolering og rensning av et produkt som er akseptabelt for de nedenfor beskrevne formål, som illustrert med dicykloheksylamin-saltet i eksemplene. Saltene fremstilles ved at syreformen av forbindelsen omsettes med en ekvivalent av basen som gir det ønskede basiske ion, i et medium i hvilket saltet utfelles, eller i et vandig medium, hvorefter produktet lyofiliseres. Den frie syreform kan erholdes fra saltet ved vanlig nøytralisa-sjon, f.eks. med kaliumbisulfat, saltsyre osv. ;Forbindelsen med formel I hvor R^er hydrogen, R,--CO-eller substituenten av disulfidtypen, særlig hvor R^er hydrogen, er nyttige som hypotensive midler. De hemmer omdannelsen av dekapeptidet angiotensin I til angiotensin II og er derfor nyttige til å lindre hypertensjon som er tilknyttet angiotensin. Virkningen av enzymet renin på angiotensinogen, et pseudoglobulin i blodplasma, fremkaller angiotensin I. Angiotensin I omdannes ved hjelp av angiotensin-omdannende enzym (ACE) til angiotensin II. Sistnevnte er en aktiv pressor-substans som er foreslått som den komponent som forårsaker forskjellige former for hypertensjon i forskjellige pattedyr, f.eks. rotter og hunder. Forbindelsene som fremstilles ifølge oppfinnelsen, griper inn i angiotensinogen ->- (renin) ->- angiotensin I -> (ACE) angiotensin II forløpet ved å hemme angiotensin-omdannende enzym og redusere eller eliminere dannelsen .av pressor-substansen angiotensin II. Ved å administrere et preparat inneholdende én eller en kombinasjon av forbindelser med formel I kan man lindre den hypertensjon i pattedyr som skyldes angiotensin. En enkel dose eller fortrinnsvis.to til fire separate daglige doser, gitt på grunnlag av ca. 0,1 til 100 mg pr. kg. kroppsvekt pr. dag, fortrinnsvis ca. 1 til 15 mg pr. kg. kroppsvekt pr. dag, er passende til å redusere, blodtrykket. Forbindelsen administreres fortrinnsvis oralt, men parenterale■administreringsveier kan også anvendes så som subkutan, intramuskulær, intravenøs eller intraperitoneal administrering. ;Forbindelsene fremstilt ifølge oppfinnelsen kan også anvendes i kombinasjon med et diuretisk middel for behandling av hypertensjon. Et kombinasjonsprodukt som omfatter en. forbindelse fremstilt ifølge oppfinnelsen, og et diuretisk middel kan administreres i en effektiv mengde som omfatter (for et pattedyr på 70 kg) en total daglig dose på ca. 30- til 600 mg, fortrinnsvis ca. 30 til 300 mg, av den nye forbindelsen og ca. 15 til 300 mg, fortrinnsvis ca. 15 til 200 mg av et-diuretisk middel, til et pattedyr som har behov for det. Eksempler på diuretika som kan anvendes i kombinasjon med en forbindelse fremstilt ifølge oppfinnelsen, er tiazid-diuretika, f.eks. klortiazid, hydroklortiazid, flumetiazid, hydroglunetiasid, benzdroflumetiazid, methchlotiazid, triklormetiazid, polytiazid eller benztiazid, så vel som etakrynsyre, tikrynafen, klortalidon, furosemid, musolimin, bumetanid, triamteren, amilorid og spironolakton, og salter av slike forbindelser. ;De nye forbindelser med formel I kan tilberedes for anyendeise-for å redusere blodtrykket, i slike preparater som ;tabletter, kapsler eller eliksirer for oral administrering eller i sterile oppløsninger eller suspensjoner for parenteral administrering. Ca. 10 til ca. 500 mg av en forbindelse eller en blanding av forbindelser med formel I blandes med et fysiologisk godtagbart bæremiddel, hjelpestoff, bindemiddel, konserverings-middel, stabiliseringsmiddel, smaksstoff osv. i en enhetsdose-form i henhold til godtatt farmasøytisk praksis. Mengden av aktivt stoff i disse preparater er slik at man får passende dosering i det angitte område. ;Illustrerende fremgangsmåtedetaljer er gitt i de følgende eksempler for de forskjellige reaksjoner. Disse eksempler representerer foretrukne utførelsesformer og tjener også som modell for fremstilling av andre forbindelser. Alle temperaturer er i °C. ;Eksempel 1, ;1-[ 3-( acetyltio)- 1- oksopropy1]- 4- okso- L- prolin;a) N- karbobenzyloksy- 4- hydroksy- L- proljn;26,5 g (0,02 mol) 4-hydroksy-L-prolin og 32,8 ml (0,23 mol) benzylklorformiat omsettes i 200 ml vann og 100 ml aceton i nærvær av 20. g (0,02 mol) kaliumbikarbonat og 69,2 g (0,50 mol) kaliumkarbonat og opparbeides med 90 ml konsentrert saltsyre som beskrevet i Can. J. Biochem & Physiol. 21_, 584 (1959) for å gi N-karbobenzyloksy-4-hydroksy-L-prolin. Dette produkt omsettes med cykloheksylamin for å danne cykloheksylaminsaltet, utbytte 69 g, sm.p. 193-195°. Saltet (34 g) nøytraliseres med N saltsyre for å gi 27 g fri syre som et farveløst glass [ct]^<6>-70° (c, 1% i kloroform) . ;b) N- karbobenzyloksy- 4- ke to- L- prolin;21,5 g (0,81 mol) N-karbobenzyloksy-4-hydroksy-L-prolin oksyderes i 1,2 liter aceton med 83 ml 8N kromsyre i svovelsyre . som . beskrevet i J. A. C. S. 79.' 189 (1957). For å lette den påfølgende filtrering av kromsalter, settes 30 g "Celite" (diatoméjord) til acetonoppløsningen før innføring av oksydasjonsmidlet. En luftrører anvendes. Reaksjonsblandingen filtreres, og acetonfiltratet konsentreres til ca. 300 ml før fortynning med 1 liter kloroform. Oppløsningen vaskes med .300 ml mettet natriumklorid (4 ganger), tørres (MgSO^), filtreres og oppløsningsmidlet avdampes for å gi N-karbobenzyloksy-4-keto-L-prolin (22,8 g) som krystalliseres fra eter (50 ml) - heksan (150 ml) for å gi 17,2 g (81%) produkt, sm.p. 99-101°, [a]^<6>+ 17° (c, .1% i kloroform). ;c) 4- keto- L- prolin- hydrobromid;Til 4,0 g (0,015 mol) N-karbobenzyloksy-4-keto-L-prolin settes 20 ml hydrogenbromid i eddiksyre (30-32%). Blandingen settes i bevegelse flere ganger i løpet av en periode på 8 minutter. Ved slutten av denne periode (brusing.har stoppet), dekkes den guloransje oppløsning med 250 ml eter, og det gummi-aktige produkt utgnies. Eteren kastes, og det resulterende, klebrige, faste stoff utgnies med frisk eter og til slutt med 50 ml acetonitril for å gi 4-keto-L-prolin-hydrobromid som et krystallinsk fast stoff med vekt 2,7 g (85%), sm.p. 153-155° (dek.), [a]^<6>-49° (c, 1% i vann). ;d) 1- [ 3- ( acetyltio)- 1- oksopropy1]- 4- okso- L- prolin;En omrørt oppløsning av 4,1 g (0,0195 mol) 4-keto-L-proiin-j-hydrobromid i 50 ml vann avkjøles til 5° og behandles porsjonsvis med fast natriumkarbonat (skumming reguleres ved å tilsette noen få dråper eter) til pil 8,0 (ca. 2 g nødvendig). Under fortsatt omrøring og avkjøling tilsettes derefter ' porsjonsvis 3,5 g (0,012 mol) 3-acetyltiopropionylklorid i 5 ml etylacetat ved hjelp av en pipette mens pH-verdien holdes ved 7,0-8,0 ved dråpevis tilsetning av 25% (vekt/volum) riatrium-karbonatoppløsning (ca. 10 ml). Efter ca. 10 minutter stabiliseres pH-verdien ved 8,0-8,4. Efter fortsatt omrøring og avkjøling i totalt 1 time vaskes oppløsningen med etylacetat (2 x 50 ml), dekkes med 50 ml etylacetat, omrøres, av-kjøles, surgjøres forsiktig med konsentrert saltsyre til pH 2,0, mettes med natriumklorid, og lagene adskilles. Den vandige fase ekstraheres med ytterligere etylacetat (3 x 50 ml), de samlede organiske lag tørres (MgSO^), og oppløsningsmidlet avdampes, til slutt ved 0,2 mm for å gi 4,8 g av et gul-oransje glass lignende residuum. Dette residuum oppløses i 35 ml etylacetat og behandles med en oppløsning av 3,5 g dicykloheksy1-amirf i 5 ml etylacetat. Ved kimtilsetning og gnidning utskilles krystallinsk 1-[3 - (acetyltio-l-oksopropyl)]-4-okso-L-prolin-dicykloheksylaminsalt, vekt efter avkjøling natten over, 2,7 g (nesten farveløst), sm.p. 191-193° (dek.), [a]^<6>-24° (c, 1% i CHC13) ;Dette dicykloheksylaminsalt omdannes til den,frie syre ved å suspendere det i etylacetat og behandle det med 45 ml 10%ig kaliumbisulfat og omrøre inntil man får to lag. Efter separering ekstraheres den vandige fase med etylacetat (4 x 75 ml), de organiske lag samles, tørres (MgSO^), og oppløsningsmidlet avdampes for å gi 3,7 g av et lysegult, glasslignende materiale.. ;Analyse: Beregnet for C^H^NC^S: C 46 , 32 , H 5,05, N 5,40, S 12,37 Funnet: C 47,05, H 5,50, N 5,18, S 12,07. ;Eksempel 2 ;1-( 3- merkapto- l- oksopropyl)- 4- okso- L- prolin;Argon føres gjennom en kold oppløsning av 9 ml konsentrert ammoniumhydroksyd i 22 ml vann i 30 minutter. Dette materiale settes derefter under avkjøling og under et teppe av argon til 3,65 gi (0,014 mol) 1-[3-(acetyltio)-1-oksopropy1]-4-okso-L-prolin. Ca. 30 minutter er nødvendig for å oppløse prolin-utgangsmaterialet ved hjelp av en magnetisk rører. Omrøring under argon fortsettes ved romtemperatur i ytterligere 2 'timer, hvorefter oppløsningen ekstraheres med 30 ml etylacetat (denne og påfølgende operasjoner utføres i størst mulig utstrekning under en argonatmosfære). Det vandige lag avkjøles, omrøres, dekkes over med 30 ml etylacetat og surgjøres porsjonsvis med 1:1 HC1. Natriumklorid tilsettes, lagene adskilles, og den vandige fase ekstraheres med ytterligere etylacetat (3 x 30 ml). Det blir tilbake en brun, gummiaktig fraksjon som er uoppløselig i begge faser. Efter tørring over MgSO^inndampes de samlede etylacetatlag for å gi et stort sett fast residuum som blir ;et amorft stoff når det utgnies med eter, og inndampningen gjentas for å gi 1,4 g av et blekgult materiale. ;1,3 g av dette materiale gnies under 50 ml eter, avkjøles under argon i 1 time, filtreres, vaskes med eter og tørres i vakuum for å gi 1,0 g 1-(3-merkapto-l-oksopropyl)-4-okso-L-pfolin, Rf 0,67 (metanol på silikagel, fremkalt i joddamp). Analyse : Beregnet for CgH^NO^-0,5H20: C 42 , 46, H 5,35, N 6,19, S 13,71 Funnet: C 42,66, H 5,39, N 6,30, S 13,30. ;Eksempel 3 ;( S)- 1-[( 3- acetyltio)- 2- metyl- l- oksopropyl)- 4- okso- L- prolin;Ved å følge fremgangsmåten ifølge eksempel 1, men ved anvendelse av D-3-acetyltio-2-metylpropionylklorid istedenfor 3-acetyltiopropio'ny lklorid, får man (S)-1-[(3-acetyltio)-2-metyl-l-oksopropyl]-4-okso-L-prolin. ;Eksempel 4 ;( S)- 1-( 3- merkapto- 2- metyl- l- oksopropy1)- 4- okso- L- prolin ;Produktet fra eksempel 3 behandles med ammoniumhydroksyd ved fremgangsmåten ifølge eksempel 2 for å gi (S)-1-(3-merkapto-2-metyl-l-oksopropyl)-4-okso-L-prolin. ;Eksempel. 5 ;1- [ ( 3- acetyltio) - 2- trif luormety 1- 1- oksopropy 1 ] - 4- okso- L- prolin ;a) D, L- 3-( acetyltio)- 2- trifluormetylpropionsyre;i ;a-trifluormetylakrylsyre (10 g, 0,071 mol)■[fremstilt i henhold til fremgangsmåten beskrevet i J. Chem. Soc. 1954, s. 371] avkjøles i et salt-is-vann-bad, omr.øres og behandles porsjonsvis med 5,7 ml (0,075 mol) 97%ig tioleddiksyre. Efter tilsetningen omrøres den gule væske under avkjøling i 1 time, får oppvarmes til romtemperatur og destilleres for å gi 14 g (91%) D,L-3-(acetyltio)-2-trifluormetylpropionsyre som en lysegul olje, k.p. 149-153°/13 mm. Materialet stivner ved lagring under avkjøling. ;b) • D, L- 3-( acetyltio)- 2- trifluormetylpropionylklorid D,L-3-(acetyltio)-2-trifluormetylpropionsyre (7 g,;0,032 mol) behandles med 18 ml (0,25 mol) redestillert tio.nyl-klorid, og blandingen tilbakeløpsbehandles i 3 timer. Efter fjernelse av overskudd av tionylklorid på en rotasjonsinndamper, ;f;destilleres residuet for å gi 6,8 g D,L-3-(acetyltio)-2-trifluormetylpropionylklorid som en blekgul olje; k.p. 80-82°/16 mm. ;c) 1- [ 3- acetyltio)- 2- trifluormetyl- l- oksopropyl]- 4- okso-L- prolin ;D,L-3-(acetyltio)-2-trifluormetylpropionylklorid omsettes med 4-keto-L-prolin-hydrobromid i henhold til fremgangsmåten ifølge eksempel .1 (d) for å gi 1-[(3-acetyltio)-2-trifluormety1-1-oksopropy 1] -4-okso-l-prolin . Denne blanding av diastereo-' • > isomerer kan derefter separeres på vanlig måte. ;Eksempel 6 ;1-( 3- merkapto- 2- tri fluormety1- 1- oksopropyl)- 4- okso- L- prolin ;Produktet frå eksempel 5 (i form av den diastereoisomere blanding eller som de separerte isomerer) hydrolyseres med konsentrert ammoniakk i henhold til fremgangsmåten ifølge eksempel 2 for å gi 1-(3-merkapto-2-trifluormetyl-l-oksopropyl)-4-okso j-L-prolin. ;Eksempel 7 ;( S)- 1- ( 3- merkapto- 2- merkaptometyl- l- oksopropy1)- 4- okso- L- prolin a) ( S)- l-[ 3-( acetyltio)- 2-( acetyltiometyl)- 1- oksopropy1]-4- okso- L- prolin. ;Ved å følge fremgangsmåten ifølge eksempel 1, men ved anvendelse av D-3-acetyltiometyl-3-acetyltiopropionylklorid istedenfor 3-acetyltiopropionylklorid i del (d), får man (S)-1-[3-(acetyltio)-2-(acetyltiome tyl)-1-oksopropy1]-4-okso-L-prolin. ;b) ( S) - 1- ( 3- me. rkapto- 2- merkaptometyl- l- oksopropyl) - 4- okso-L- prolin ;Produktet fra del (a) hydrolyseres med konsentrert ammoniakk i henhold til fremgangsmåten ifølge eksempel 2 for å gi (S) -1- (3-merkap'to-2-merkaptome.ty 1-1-oksopropyl) -4-okso-L-prolin. ;Eksempel 8 ;1-( 3- merkapto- 2- metyltio- l- oksopropy1)- 4- okso- L- prolin;a) 3-( acetyltio)- 2-( metyltio) propionsyre;12,5 g (0,094 mol) metyl-2-(metyltio)-akrylat [fremstilt fra mety1-2-klorakrylat i henhold til fremgangsmåten ifølge Gundesmann et al., Chemische Berichte 9_4, 3254 (1916)] omrøres med IN vandig natriumhydroksyd (94 ml) med isavkjøling. Blandingen får oppvarmes til omgivelsestemperatur og omrøres derefter i 5 timer. Den. resulterende oppløsning vaskes med eter og surgjøres derefter til pH 2 med konsentrert saltsyre. Det faste bunnfall ekstraheres inn i metylenklorid, og opp-løsningen vaskes med mettet natriumklorid, og oppløsningsmidlet avdampes .• Det faste residuum, 2-(metyltio)-akrylsyre, sm.p. 70-75°; anvendes umiddelbart ved den følgende omsetning. ;i ;Ekvimolare mengder av 2-(metyltio)akrylsyre og tioleddiksyre blandes under argon og omrøres ved 80° i flere timer for å gi 3-(acetyltio)-2-(metyltio)propionsyre. ;b) 3-( acetyltio)- 2-( metyltio) propionsyreklorid 3-(acetyltio)-2-(metyltio)propionsyre tilbakeløpsbehandles ;i tionylklorid i 2 timer. Reaksjonsblandingen destilleres for å fjerne overskudd av tionylklorid, og produktet destilleres i vakuum for å gi 3-(acetyltio)-2-(metyltio)propionsyreklorid. ;c) 1-[ 3-( acetyltio)- 2- metyltio- l- oksopropyl]- 4- okso- L- prolin 3-(acetyltio)-2-(metyltio)propionsyreklorid omsettes med ;4-keto-L-prolin-hydrobromid i henhold til fremgangsmåten ifølge eksempel 1 (d) for å gi 1-[3-(acetyltio)-2-metyltio-l-oksopropyl] -4-okso-L-prolin. ;d) 1-( 3- merkapto- 2- metyltio- l- oksopropyl)- 4- okso- L- prolin Produktet fra del (c) hydrolyseres med konsentrert ;ammoniakk i henhold til fremgangsmåten ifølge eksempel 2 for å gi 1-(3-merkapto-2-metyltio-l-oksopropyl)-4-okso-L-prolin. ;Eksempel 9;1-( 4- merkapto- l- oksobutyl)- 4- okso- L- prolin;a) ' 1-[ 4-( acetyltio)- 1- oksobutyl]- 4- okso- L- prolin;Ved å følge fremgangsmåten ifølge eksempel 1, men ved ;anvendelse av 4-acetyltiobutyroylklorid istedenfor 3-acetyltiopropionylklorid i del (d), får man 1-[4-(acetyltio)-1-oksobutyl]-4-okso-L-prolin. ;b) 1-( 4- merkapto- l- oksobutyl)- 4- okso- L- prolin ;Produktet fra del (a) hydrolyseres med konsentrert ;ammoniakk i henhold til fremgangsmåten ifølge eksempel 2 for å gi 1-(4-merkapto-l-oksobutyl)-4-okso-L-prolin. ;Eksempel 10;1-( 2- merkapto- l- oksoetyl)- 4- okso- L- prolin ;a) 1-[ 2-( acetyltio)- 1- oksoetyl]- 4- okso- L- prolin;Ved å følge fremgangsmåten ifølge eksempe 1, men ved ;anvendelse av acetyltioacetylklorid istedenfor 3-acetyltiopropionylklorid i del (d), får man 1-[2-(acetyltio)-1-okso-etyl] -4-okso-L-prolin . ;b) 1-( 2- merkapto- l- oksoetyl)- 4- okso- L- prolin ;Produktet fra del (a) hydrolyseres med konsentrert ammoniakk i henhold til fremgangsmåten ifølge eksempel 2 for å gi 1-(2-merkapto-l-oksoetyl)-4-okso-L-prolin. ;Eksempel 11 ;. 1-( 3- merkapto- 2, 2- dimetyl- l- oksopropyl)- 4- okso- L- prolin;a) 1-[ 3- ( acetyltio)- 2, 2- dimetyl- l- oksopropyl]- 4- okso- L- prolin Ved å følge fremgangsmåten ifølge eksempe 1, men ved ;anvendelse av 3-acetyltio-2,2-dimetylpropionylklorid istedenfor 3-acetyltiopropionylklorid i del (d), får man 1-[3-(acetyltio)-2,2-dimety1-1-oksopropyl]-4-okso-L-prolin. ;b) 1-( 3- merkapto- 2, 2- dimetyl- l- oksopropyl)- 4- okso- L- prolin Produktet fra del (a) hydrolyseres med konsentrert ;ammoniakk i henhold til fremgangsmåten ifølge eksempel 2, for å gi 1-(3-merkapto-2,2-dimetyl-l-oksopropyl)-4-okso-L-prolin. ;Eksempel 12 ;( S)- 1-( 3- merkapto- 2- etyl- l- oksopropyl)- 4- okso- L- prolin;a) ( S) - 1- [ 3- ( acetyltio) - 2- ety 1- 1- oksopropyl] - 4- okso- L- pr' olin Ved å følge fremgangsmåten ifølge eksempel 1, men ved ;anvendelse av D-3-acety.ltio-2-etylpropionylklorid istedenfor D-3-acetyltio-2-metylpropionylklorid i del (d), får man (S)-1-[3-(acetyltio)-2-ety1-1-oksopropyl]-4-okso-L-prolin. ;b) ( S)- 1-( 3- merkapto- 2- etyl- l- oksopropyl)- 4- okso- L- prolin ;Produktet fra del (a) hydrolyseres med konsentrert ;ammoniakk i henhold til fremgangsmåten ifølge eksempel 2 for å gi (S)-1-(3-merkapto-2-etyl-l-oksopropyl)-4-okso-L-prolin. ;Eksempel 13;i ;1-( 3- mgrkapto- l- oksopropyl)- 4- okso- L- pipekolsyre;a) 1-[ 3- ( acetyltio)- 1- oksopropy1]- 4- okso- L- pipekolsyre;i ;Ved å følge fremgangsmåten ifølge eksempel 1,. men ved anvendelse av 4-keto-L-pipekolsyre istedenfor 4-keto-L-prolin i del (d), får man 1-[3-(acetyltio)-1-oksopropyl]-4-okso-L-pipekolsyre. ;b) 1-( 3- merkapto- l- oksopropyl)- 4- okso- L- pipekolsyre ;Produktet fra del (a) hydrolyseres med konsentret ;ammoniakk for å gi 1-(3-merkapto-l-oksopropy1)-4-okso-L-pipekolsyre . ;Eksempel 14 ;( S)- 1-( 3- merkapto- 2- metyl- l- oksopropyl)- 5- okso- L- pipekolsyre;a) ( S.) - 1- [ 3 - ( acetyltio) - 2- mety 1- 1- oksopropyl] - 5- okso-L- pipekolsyre .r Ved å følge fremgangsmåten ifølge eksempel 1, men ved anvendelse av 5-keto-L-pipekolsyre istedenfor 4-keto-L-prolin i del (d) og D-3-acetyltio-2-metylpropionylklorid istedenfor acetyltiopropionylklorid i del (d), får man (S)-1-[3-(acetyltio-2-metyl-l-oksopropy1]-5-keto-L-pipekolsyre. ;b) ( S)- 1-( 3- merkapto- 2- mety1- 1- oksopropyl)- 5- keto- L- pipekolsyre Produktet fra del (a) hydrolyseres med konsentrert ammoniakk i henhold til fremgangsmåten ifølge eksempel 2 for å gi ;(S)-1-(3-merkapto-2-metyl-l-oksopropyl)-5-keto-L-pipekolsyre. ;Eksempel 15 ;1-( 3- merkapto- 2- trifluormetyl- l- oksopropyl)- 4- okso- L- prolin;a) 3-[[( 4- metoksy) fenyImetyl] tio]- 2- tri fluormetylpropiony1-k lorid ;En ufortynnet blanding av 1-trifluormetylakrylsyre (3,9 g) og 4-metoksybenzyltiol (4,3 g) omrøres ved 100-110° i 1 time. Blandingen får avkjøles til romtemperatur, og det faste stoff omkrystalliseres fra cykloheksan for å gi 3-[[(4-metoksy)fenylmetyl]tio]-2-trifluormetylpropionsyre, sm.p. 72-74°. ;Behandling av denne syre med tionylklorid gir 3-[[(4-metoksy)fenylmetyl]tio]-2-trifluormetylpropionylklorid. ;b) 1"^ [ 3 — [ [ ( 4- metoksy) fenylmetyl] tio] - 2- trifluormetyl- l- oksopropy1]- 4- okso- L- prolin ;3-[[(4-metoksy)fenylmetyl]tio]-2-tri fluormetylpropiony1-kloridet fra del (a) omsettes med 4-keto-L-prolin for å gi 1-[3-[[(4-metoksy)fenylmetyl]tio]-2-tri fluormety1-1-oksopropyl]-4-okso-L-prolin. ;c) 1-( 3- merkapto- 2- trifluormetyl- l- oksopropyl)- 4- okso- L- prolin Produktet fra del (b) blandes med tri fluoreddiksyre og ;anisol under nitrogen. Oppløsningsmidlene fjernes under vakuum for å gi som residuum 1-(3-merkapto~2-trifluormetyl-l-oksopropyl) -4-okso-L-prolin. ;Eksempel 16 ;( S)- 1-( 3- merkapto- 3- metyl- l- oksopropyl)- 4- okso- L- prolin;a) ( S)- 1-[ 3-( acetyltio)- 3- metyl- l- oksopropyl]- 4- okso- L- prolin f Ved å følge fremgangsmåten ifølge eksempel 1, men ved ;anvendelse av D-3-acetyltio-3-metylpropionylklorid istedenfor 3-acetyltiopropionylklorid i del (d), får man (S)-l-[3-(acetyltio)-3-metyl-l-oksopropyl]-4-okso-L-prolin.■ ;b) ( S)- 1-( 3- merkapto- 3- mety1- 1- oksopropyl)- 4- okso- L- prolin Produktet fra del (a) hydrolyseres med konsentrert ;ammoniakk for å gi (S)-1-(3-merkapto-3-metyl-l-oksopropyl)-4-okso-L-prolin. ;Eksempler 17- 25;Ved å følge fremgangsmåten i følge.eksempel 1, men ved at det istedenfor 3-acetyltiopropionylklorid anvendes syrekloridet angitt nedenfor i spalte I, får man acylmerkapto-produktet angitt nedenfor i spalte II. ; Eksempel 26 ;( S) - 1- ( 3- merkapto- 2- mety. l- l- oksopropyl) - 4- okso- L- prolin-l- adamantanaminsalt ;Produktet ifølge eksempel 4 kan også fremstilles i henhold til følgende fremgangsmåte. ;a) N- karbobenzyloksy- 4, 4- dime toksy- L- prolin- metylester;En omrørt oppløsning av 7,8 g. (0,03 mol) N-karbobenzyloksy-4-keto-L-prolin fra eksempel 1 i 60 ml metanol behandles med 96 ml trimetylortoformiat, fulgt av 0,6 ml konsentrert svovelsyre, og får stå ved romtemperatur natten over. ;Den blekgule oppløsning omrøres, behandles med 1,5 g kaliumkarbonat, fulgt av 30 ml vann, og mesteparten av opp-løsningsmidlet fjernes på en rotasjonsinndamper for å gi et sirupaktig residuum som ristes med 30 ml vann og 30 ml kloroform. Efter separering av lagene, ekstraheres den vandige fase med ytterligere kloroform (3 x 30 ml) , og de' samlede organiske lag vaskes med 45 ml mettet natriumklorid-oppløsning og tørres (MgSO^.) . Avdampning av oppløsningsmidlet gir 8,4 g (88%) N-karbobenzyloksy-4,4-dimetoksy-L-prolin-metylester. ;b) N- karbobenzyloksy- 4, 4- dimetoksy- L- prolin;Esteren (8,4 g, 0,026 mol) fra del (a) oppløses i 80 ml ;metanol, behandles dråpevis ved -1° til 4° méd 18. ml (0,036 mol) 2N natriumhydroksyd, idet den holdes ved 0° i 1 time, og ved romtemperatur natten over. Efter fjernelse av ca. halvparten av oppløsningsmidlet på en rotasjonsinndamper, fortynnes opp-løsningen med 150 ml vann, vaskes med 100 ml eter (vaskevæsker kastes) , surgjøres under avkjøling med 63 ml 1:1 saltsyre til pH 2, og ekstraheres med etylacetat (4 x 750 ml). De samlede ekstrakter vaskes med 50 ml mettet natriumklorid-oppløsning, tørres (MgSO^), og oppløsningsmidlet avdampes for å gi 8,0 g av en blekgul, viskøs olje. Oljen oppløses i 35 ml etanol, behandles med 3,0 g cykloheksylamin i 10 ml etanol og fortynnes til 500 ml med eter. Ved kimpodning og gnidning utskilles det krystallinske N-karbobenzyloksy-4,4-dimetoksy-L-prolin-cykloheksylaminsalt; vekt efter avkjøling natten over, 7,0 g, sm.p. 157-159° (s. 151) [«]^<6>-34° (c, 1% i EtOH). Dette materiale omkrystalliseres fra 100 ml acetonitril for å gi saltet som et farveløst, fast stoff, sm.p. 158-160° (s. 154°), [a]^<6>-33° (c, 1% i EtOH). ;N-karbobenzyloksy-4,4-dimetoksy-L-prolin-cykloheksylaminsaltet suspenderes i 40 ml•etylacetat, omrøres og behandles med 25 ml IN saltsyre. Når man får to klare lag, adskilles de, deri vandige fase ekstraheres med ytterligere etylacetat (3 x 40 ml), de.samlede organiske lag tørres (MgSO^), og opp-løsningsmidlet avdampes, til slutt ved 0,2 mm og 40° for å gi 7.2 g (70%) N-karbobenzyloksy-4,4-dimetoksy-L-prolin som en blekgul, viskøs sirup. ;c) 4, 4- dimetoksy- L- prolin;En oppløsning av N-karbobenzyloksy-4,4-dimetoksy-L-prolin (72 g, '0,022.11101) i 210 ml metanol-vann (2:1) behandles med 2.3 g 5% palladium-kull og ristes på et Parr hydrogenerings-apparat i 6 timer. Katalysatoren frafiltreres under nitrogen, i vaskes med metanol, og de samlede filtrater inndampes, til slutt ved 0,1-0,2 mm for å gi et delvis krystallinsk residuum. Dette residuum opptas i 200 ml metanol, og inndampningen gjentas. Når det faste stoff gnies under eter (inndampning gjentas igjen) får man 3,6 g (95%) nesten farveløst 4,4-dimetoksy-L-prolin, sm.p. 192-194° (dek.); [a]^<6>-47° (c, 1% i MeOH). ;En prøve omkrystallisert fra metanol-eter er farveløs og smelter ved 19.7-198° (dek.); [ a]^ 6 -49° (c, 1% i MeOH). ;d) ( S)- 1-[ 3-( acetyltio)- 2- mety1- 1- oksopropyl]- 4, 4- dimetoksy-L- prolin ;En omrørt oppløsning av 3,3 g (0,019 mol) 4,4-dimetoksy-L-prolin i 50 ml vann avkjøles til 5° og bringes til pH 8,5 ;ved tilsetning av 25% natriumkarbonatoppløsning (vekt/volum). Under fortsatt omrøring og avkjøling tilsettes en oppløsning av 3,8 •"g (0,021 mol) D-3-acetyltio-2-metylpropanoylklorid i 5 ml eter porsjonsvis mens pH-verdien holdes ved 7,5-8,5 ved dråpevis tilsetning av 25%ig natriumkarbonatoppløsning. Når pH-verdien har stabilisert seg på 8,2-8,4 (efter ca. 15 minutter), fortsettes omrøring og avkjøling i. totalt 1 time. Oppløsningen vaskes derefter med 50 ml etylacetat (vaskevæsker kastes) dekkes med 50 ml etylacetat, avkjøles, omrøres, surgjøres forsiktig med ;1:1 saltsyre til pH 2,0, mettes med natriumklorid, og lagene adskilles. Den vandige fase ekstraheres med ytterligere etylacetat (3 x 50 ml), de samlede organiske lag tørres (MgSO^), og oppløsningsmidlet avdampes, til slutt ved 0,2 mm, for å gi 6,7 g sirupaktig produkt. Denne sirup behandles i 70 ml etylacetat med 3,9 g dicykloheksylamin for å gi 6,5 g ;farveløst (S)-1-[3-(acetyltio)-2-metyl-l-oksopropyl]-4,4-dimetoksy-L-prolin-dicykloheksylaminsalt i to porsjoner (3,1 g og 3,4 g) , sm.p. 158-160° (s. 145°), [2.]^<6>-71° (c, 1% i EtOH).. ;Efter omkrystallisering fra 20 ml varm etylacetat - 60 ml heksan veier det farveløse, faste salt 6,0 g, sm.p. 158-166° (s, 155°), [a]^<5>-69° (c, 1% i EtOH). ;Dicykloheksylaminsåltet omdannes til den frie syre ved suspendering av 5,0 g i 50 ml etylacetat, avkjøling og behandling med 60 ml 10%ig kaliumbisulfatoppløsning for å gi to klare lag. Efter adski Helse ekstraheres den vandige fase med etylacetat (3 x 50 ml) , de samlede organiske- lag tørres (MgSO^), og oppløsningsmidlet avdampes, til slutt ved 0,l'-0,2 mm og 45° for å gi 4,1 g (69%) (S)-1-[3-(acetyltio)-2-metyl-l-oksopropyl] -4,4-dimetoksy-L-prolin som et viskøst, nesten glasslignende materiale, [a]^ -112° (c, 1% i EtOH) . ;e) ( S)- 1-( 3- merkapto- 2- metyl- l- oksopropyl)- 4, 4- dimetoksy-L- prolin ;Argon føres gjennom en kald oppløsning av 8,5 ml konsentrert ammoniumhydroksyd i 20 ml vann i 0,25 time. Sistnevnte settes derefter under avkjøling og under et teppe ;av argon til 4,1 g (0,013 mol) (S)-1-[3-(acetyltio)-2-metyl-l-oksopropyl ]-4,4-dimetoksy-L-prolin, og blandingen holdes i bevegelse i et isbad inntil man får en blekgul oppløsning (ca. 15 minutter). Omrøring under argon fortsettes ved romtemperatur i ytterligere 2 timer, derefter ekstraheres opp-løsningen med 30 ml etylacetat (denne og påfølgende operasjoner foretas i størst mulig utstrekning under en argonatmos fære) . ;Det vandige lag avkjøles, omrøres, dekkes med 30 ml. etylacetat og surgjøres porsjonsvis med ca. 16 ml 1:1 saltsyre. Lagene adskilles, den vandige fase ekstraheres med ytterligere etylacetat (3 x 30 ml), de samlede etylacetatlag tørres (MgSO^), ;og oppløsningsmidlet avdampes for å gi 3,5 g (100%) ;(S)-1-(3-merkapto-2-mety1-1-oksopropyl)-4,4-dimetoksy-L-prolin som en farveløs, viskøs sirup, [<*]^ -72° (c, 1% i EtOH). The term "hydrolytically removable protecting group" used in the definition of R 1 denotes a group which may be removed by conventional hydrolysis or ammonolysis. Acyl groups with the formula R^-CO- are suitable for this purpose, where <*>R^ can be lower alkyl with 1 to 7 carbon atoms, lower alkyl substituted with one or more chlorine, bromine or fluorine groups, - (CH2 )^-cycloalkyl where the term "cycloalkyl" denotes saturated rings with 3 to 7 carbon atoms, preferably cyclohexyl, an aryl group such as ; a heterogroup such as or ; where r is 0, 1, 2 or 3; ;RD, is hydrogen, lower alkyl with 1 to 4 carbon atoms, especially methyl, lower alkoxy with 1 to 4 carbon atoms, especially methoxy, lower alkylthio with 1 to 4 carbon atoms, especially methyl, chlorine, bromine, fluorine, trifluoromethyl or hydroxy; ; and X is oxygen or sulfur. Preferred groups are the lower alkanoyl groups with up to 4 carbon atoms, especially acetyl, and benzoyl. The term "chemically removable protecting group" used in the definition of R 1 denotes such groups as p-methoxy, p-methoxybenzylcarbonyl, trityl, t-butoxycarbonyl, etc. These groups may be removed after completion of the acylation reaction, in various ways such as by treatment with trifluoroacetic acid and anisole. Preferred compounds of formula I are the L-proline-containing derivative, ie p and q are both 1, and R is hydrogen. In the case of the mercaptoacyl side chain, preferred end products are those compounds where R 1 is hydrogen; m is 0 or 1; is hydrogen; and R^and R ? are both lower alkyl with 1 to 4 carbon atoms, especially both methyl, or R^ is hydrogen and R^ is hydrogen, lower alkyl with 1 to 4 carbon atoms, especially methyl, trifluoromethyl, methylthio or mercaptomethyl. Also preferred as both intermediates and as final products are the above side chains where R is lower alkanoyl with 1 to 4 carbon atoms, especially acetyl or benzoyl. Particularly preferred as end products are the compounds of formula I with the mercaptoacyl side chain where R^ is hydrogen; m is 1; R 1 and R 2 are hydrogen; R 2 is methyl or hydrogen; and when R 2 is methyl, the asymmetric carbon atom to which R 2 is attached is in the D configuration. ;The compounds with formula I are prepared by a keto-substituted proline or pipecolic acid with the formula ;(II) ; ; is coupled with an acid or its chemical equivalent of the formula ;(III) ; where ; is hydrogen or a protecting group which can be hydrolytically or chemically removed to form the product of the formula (IV) ; ; This reaction can be carried out in the presence of a coupling agent such as dicyclohexylcarbodiimide or the like, or the acid can be activated by the formation of its mixed anhydride, symmetrical anhydride, acid halide, active ester or by using Woodward's reagent K,N-ethoxycarbonyl1-2-ethoxy- 1,2-dihydroquinoline or the like. For an overview of acylation methods, reference can be made to Methoden der Organischen Chemie (Houben-Weyl), vol. XV, Part II, pp. 1 et seq. (1974). Preferably, the acid halide, especially the acid chloride, of formula III is reacted with the acid of formula II. If the proline or pipecolic acid derivative of formula II is reacted in ester form, the resulting ester product can be converted into the free acid, i.e. R is hydrogen, in the usual way. If e.g. R is ethyl, this protecting ester group can be removed by saponification. The product of formula IV is preferably isolated and purified by crystallization, e.g. by forming the dicyclohexylamine salt and then converting the salt to the free acid form-by treatment with an aqueous solution of an acid, such as potassium hydrogen sulfate. The product of formula IV containing the acyl group R^-CO- can be converted into the products of formula I where R^ is hydrogen, by ordinary hydrolysis or by ammonolysis. The products of formula I where R^ and R^ are different from -(CH„) -SH and R, are 2 n 4 ; ; is obtained by oxidizing a product of formula I where R^ is hydrogen directly with iodine. The esters of formula I where R is lower alkyl can be obtained from the carboxylic acid compounds, i.e. where R is hydrogen, by usual esterification methods, e.g. by esterification with a diazoalkane such as diazomethane, et. 1-alkyl-3-p-tolyltriazene, such as 1-n-butyl 1-3-p-tolyltriazene, or the like. The compounds of formula I can also be prepared by removing protecting group(s) according to usual methods from a keto-substituted proline or pipecolic acid product of formula I which has the keto function protected with the usual protecting groups such as e.g. a protecting' ketal group, e.g. a dialkyl ketal such as e.g. ;(V) ; ; from which the protecting groups can be removed by hydrolysis, e.g. with an aqueous solution of hydrochloric acid at room temperature. The compounds of formula V may be prepared by starting with an N-carbobenzyloxy-keto-substituted proline or pipecolic acid derivative of formula II, which is then treated with methanol in the presence of trimethy1-orthoformate and concentrated sulfuric acid, and the N-protecting group is then removed by hydrogenolysis in the presence of a palladium-charcoal catalyst to form the dimethoxy intermediate of the formula ;(VI) ; ; The intermediate of formula VI is then coupled with an acid or its chemical equivalent of formula III to form the dimethoxy compounds of formula V. Reference should also be made to the following publications which provide further illustrative information regarding the preparation of starting materials and intermediates: US Patents 4,046,889, 4,105,776, 4,154,935 and 4,116,962; Can. J. Biochem. & Physiol. _3_Z'583-587 (1959); JACS 79.'s. 185-192 (1957); JACS 79, pp. 192-197, (1957); Bull. Soc. Chem., 1965(8), pp. 2253-2259; and Aus. J. Chem. 20, pp. 1493-1509 (1967). The methods illustrated here can be used as general methods for synthesis of the compounds and separation of isomers that can be used in the method according to the invention. Further illustrative details are shown in the examples which also serve as models for the preparation of other compounds from the same group. The new compounds form basic salts with a number of inorganic or organic bases. The salt-forming ion derived from such bases may be metal ions, e.g. aluminium, alkali metal ions such as sodium or potassium, alkaline earth metal ions such as calcium or magnesium, or an amine salt ion, a number of which are known for this purpose, e.g. aralkylamines such as dibenzylamine, N,N-dibenzylethylenediamine, lower alkylamines such as methylamine, 't-butylamine,. procaine, lower alkyl piperidines such as N-ethylpiperidine, cycloalkylamines such as cyclohexylamine or dicyclohexylamine, 1-adamantanamine, benzatane or salts derived from amino acids such as arginine, lysine or the like. The physiologically acceptable salts such as the sodium or potassium salts can be used medicinally as described below, and are preferred. These and other salts which are not necessarily physiologically acceptable are useful for the isolation and purification of a product which is acceptable for the purposes described below, as illustrated by the dicyclohexylamine salt in the Examples. The salts are produced by reacting the acid form of the compound with an equivalent of the base that gives the desired basic ion, in a medium in which the salt is precipitated, or in an aqueous medium, after which the product is lyophilized. The free acid form can be obtained from the salt by normal neutralization, e.g. with potassium bisulphate, hydrochloric acid, etc. The compound of formula I wherein R^ is hydrogen, R^—CO—or the disulfide-type substituent, especially where R^ is hydrogen, are useful as hypotensive agents. They inhibit the conversion of the decapeptide angiotensin I to angiotensin II and are therefore useful in alleviating angiotensin-associated hypertension. The action of the enzyme renin on angiotensinogen, a pseudoglobulin in blood plasma, produces angiotensin I. Angiotensin I is converted by angiotensin-converting enzyme (ACE) to angiotensin II. The latter is an active pressor substance that has been proposed as the component that causes different forms of hypertension in different mammals, e.g. rats and dogs. The compounds produced according to the invention intervene in the angiotensinogen ->-(renin) ->-angiotensin I -> (ACE) angiotensin II course by inhibiting the angiotensin-converting enzyme and reducing or eliminating the formation of the pressor substance angiotensin II. By administering a composition containing one or a combination of compounds of formula I, the hypertension in mammals caused by angiotensin can be alleviated. A single dose or preferably two to four separate daily doses, given on the basis of approx. 0.1 to 100 mg per kg. body weight per day, preferably approx. 1 to 15 mg per kg. body weight per day, is appropriate to reduce blood pressure. The compound is preferably administered orally, but parenteral routes of administration can also be used such as subcutaneous, intramuscular, intravenous or intraperitoneal administration. The compounds produced according to the invention can also be used in combination with a diuretic agent for the treatment of hypertension. A combination product that includes a. compound prepared according to the invention, and a diuretic agent can be administered in an effective amount comprising (for a 70 kg mammal) a total daily dose of approx. 30 to 600 mg, preferably approx. 30 to 300 mg, of the new compound and approx. 15 to 300 mg, preferably approx. 15 to 200 mg of a diuretic agent, to a mammal in need thereof. Examples of diuretics that can be used in combination with a compound produced according to the invention are thiazide diuretics, e.g. chlorothiazide, hydrochlorothiazide, flumethiazide, hydroglunetiazide, benzdroflumethiazide, methchlothiazide, trichloromethiazide, polythiazide or benzthiazide, as well as ethacrynic acid, ticrynafen, chlorthalidone, furosemide, musolimine, bumetanide, triamterene, amiloride and spironolactone, and salts of such compounds. The new compounds of formula I can be prepared for the purpose of reducing blood pressure, in such preparations as tablets, capsules or elixirs for oral administration or in sterile solutions or suspensions for parenteral administration. About. 10 to approx. 500 mg of a compound or mixture of compounds of formula I is mixed with a physiologically acceptable carrier, excipient, binder, preservative, stabilizer, flavoring agent, etc. in a unit dosage form according to accepted pharmaceutical practice. The amount of active substance in these preparations is such that a suitable dosage is obtained in the indicated area. Illustrative process details are given in the following examples for the various reactions. These examples represent preferred embodiments and also serve as models for the preparation of other compounds. All temperatures are in °C. Example 1, 1-[3-(acetylthio)-1-oxopropyl]-4-oxo-L-proline; a) N-carbobenzyloxy-4-hydroxy-L-proline; 26.5 g (0.02 mol ) 4-hydroxy-L-proline and 32.8 ml (0.23 mol) of benzyl chloroformate are reacted in 200 ml of water and 100 ml of acetone in the presence of 20 g (0.02 mol) of potassium bicarbonate and 69.2 g (0. 50 mol) of potassium carbonate and worked up with 90 ml of concentrated hydrochloric acid as described in Can. J. Biochem & Physiol. 21_, 584 (1959) to give N-carbobenzyloxy-4-hydroxy-L-proline. This product is reacted with cyclohexylamine to form the cyclohexylamine salt, yield 69 g, m.p. 193-195°. The salt (34 g) is neutralized with N hydrochloric acid to give 27 g of free acid as a colorless glass [ct]^<6>-70° (c, 1% in chloroform). ;b) N-carbobenzyloxy-4-keto-L-proline; 21.5 g (0.81 mol) of N-carbobenzyloxy-4-hydroxy-L-proline are oxidized in 1.2 liters of acetone with 83 ml of 8N chromic acid in sulfuric acid. as . described in J. A. C. S. 79.' 189 (1957). To facilitate the subsequent filtration of chromium salts, 30 g of "Celite" (diatomaceous earth) is added to the acetone solution before introducing the oxidizing agent. An air stirrer is used. The reaction mixture is filtered, and the acetone filtrate is concentrated to approx. 300 ml before dilution with 1 liter of chloroform. The solution is washed with .300 ml saturated sodium chloride (4 times), dried (MgSO 4 ), filtered and the solvent evaporated to give N-carbobenzyloxy-4-keto-L-proline (22.8 g) which is crystallized from ether (50 ml ) - hexane (150 ml) to give 17.2 g (81%) product, m.p. 99-101°, [a]^<6>+ 17° (c, .1% in chloroform). ;c) 4-keto-L-proline hydrobromide; To 4.0 g (0.015 mol) N-carbobenzyloxy-4-keto-L-proline add 20 ml hydrogen bromide in acetic acid (30-32%). The mixture is set in motion several times during a period of 8 minutes. At the end of this period (effervescence has stopped), the yellow-orange solution is covered with 250 ml of ether, and the gummy product is triturated. The ether is discarded and the resulting sticky solid is triturated with fresh ether and finally with 50 mL of acetonitrile to give 4-keto-L-proline hydrobromide as a crystalline solid weighing 2.7 g (85%). sm.p. 153-155° (dec.), [a]^<6>-49° (c, 1% in water). ;d) 1- [ 3-( acetylthio)- 1- oxopropyl]- 4- oxo- L- proline; A stirred solution of 4.1 g (0.0195 mol) 4-keto-L-proiin-j-hydrobromide in 50 ml of water, cool to 5° and treat in portions with solid sodium carbonate (foaming is regulated by adding a few drops of ether) to pil 8.0 (about 2 g required). With continued stirring and cooling, 3.5 g (0.012 mol) of 3-acetylthiopropionyl chloride in 5 ml of ethyl acetate are then added portionwise by means of a pipette while the pH value is maintained at 7.0-8.0 by the dropwise addition of 25% (wt. /volume) riatrium carbonate solution (approx. 10 ml). After approx. After 10 minutes, the pH value stabilizes at 8.0-8.4. After continued stirring and cooling for a total of 1 hour, the solution is washed with ethyl acetate (2 x 50 ml), covered with 50 ml ethyl acetate, stirred, cooled, carefully acidified with concentrated hydrochloric acid to pH 2.0, saturated with sodium chloride, and the layers separated . The aqueous phase is extracted with additional ethyl acetate (3 x 50 mL), the combined organic layers are dried (MgSO 4 ), and the solvent is evaporated, finally at 0.2 mm to give 4.8 g of a yellow-orange glass-like residue . This residue is dissolved in 35 ml of ethyl acetate and treated with a solution of 3.5 g of dicyclohexyl-amirp in 5 ml of ethyl acetate. Upon addition of germ and rubbing, crystalline 1-[3-(acetylthio-l-oxopropyl)]-4-oxo-L-proline-dicyclohexylamine salt is separated, weight after cooling overnight, 2.7 g (almost colorless), m.p. 191-193° (dec.), [a]^<6>-24° (c, 1% in CHCl3) ; This dicyclohexylamine salt is converted to the free acid by suspending it in ethyl acetate and treating it with 45 ml of 10% ig potassium bisulphate and stir until you get two layers. After separation, the aqueous phase is extracted with ethyl acetate (4 x 75 ml), the organic layers are combined, dried (MgSO 4 ), and the solvent is evaporated to give 3.7 g of a light yellow, glass-like material.. ;Analysis: Calculated for C ^H^NC^S: C 46 , 32 , H 5.05, N 5.40, S 12.37 Found: C 47.05, H 5.50, N 5.18, S 12.07. ;Example 2 ;1-(3-mercaptol-ol-oxopropyl)-4-oxo-L-proline;Argon is passed through a cold solution of 9 ml of concentrated ammonium hydroxide in 22 ml of water for 30 minutes. This material is then added under cooling and under a blanket of argon to 3.65 g (0.014 mol) of 1-[3-(acetylthio)-1-oxopropyl]-4-oxo-L-proline. About. 30 minutes are required to dissolve the proline starting material using a magnetic stirrer. Stirring under argon is continued at room temperature for a further 2 hours, after which the solution is extracted with 30 ml of ethyl acetate (this and subsequent operations are carried out to the greatest extent possible under an argon atmosphere). The aqueous layer is cooled, stirred, covered with 30 ml of ethyl acetate and acidified in portions with 1:1 HCl. Sodium chloride is added, the layers are separated, and the aqueous phase is extracted with additional ethyl acetate (3 x 30 mL). A brown, rubbery fraction is left behind which is insoluble in both phases. After drying over MgSO4, the combined ethyl acetate layers are evaporated to give a largely solid residue which becomes an amorphous substance when triturated with ether, and the evaporation is repeated to give 1.4 g of a pale yellow material. ;1.3 g of this material is triturated under 50 ml of ether, cooled under argon for 1 hour, filtered, washed with ether and dried in vacuo to give 1.0 g of 1-(3-mercapto-1-oxopropyl)-4 -oxo-L-pfolin, Rf 0.67 (methanol on silica gel, developed in iodine vapor). Analysis : Calculated for CgH^NO^-0.5H20: C 42 , 46, H 5.35, N 6.19, S 13.71 Found: C 42.66, H 5.39, N 6.30, S 13.30. ;Example 3 ;(S)-1-[(3-acetylthio)-2-methyl-l-oxopropyl)-4-oxo-L-proline;By following the procedure according to example 1, but using D-3- acetylthio-2-methylpropionyl chloride instead of 3-acetylthiopropionyl chloride, you get (S)-1-[(3-acetylthio)-2-methyl-1-oxopropyl]-4-oxo-L-proline. ;Example 4 ;(S)-1-(3-mercapto-2-methyl-l-oxopropyl)-4-oxo-L-proline;The product from example 3 is treated with ammonium hydroxide by the method of example 2 to give (S) -1-(3-mercapto-2-methyl-1-oxopropyl)-4-oxo-L-proline. ;Example. 5 ;1- [ ( 3- acetylthio) - 2- trifluoromethyl 1- 1- oxopropyl 1 ] - 4- oxo- L- proline ; a) D, L- 3-( acetylthio)- 2- trifluoromethyl propionic acid; i ; a -trifluoromethylacrylic acid (10 g, 0.071 mol) [prepared according to the procedure described in J. Chem. Soc. 1954, p. 371] is cooled in a salt-ice-water bath, stirred and treated in portions with 5.7 ml (0.075 mol) of 97% thiolacetic acid. After the addition, the yellow liquid is stirred under cooling for 1 hour, allowed to warm to room temperature and distilled to give 14 g (91%) of D,L-3-(acetylthio)-2-trifluoromethylpropionic acid as a pale yellow oil, b.p. 149-153°/13 mm. The material hardens when stored under cooling. b) D,L-3-(acetylthio)-2-trifluoromethylpropionyl chloride D,L-3-(acetylthio)-2-trifluoromethylpropionic acid (7 g,;0.032 mol) is treated with 18 ml (0.25 mol) of redistilled thio. nyl chloride, and the mixture is refluxed for 3 hours. After removal of excess thionyl chloride on a rotary evaporator, the residue is distilled to give 6.8 g of D,L-3-(acetylthio)-2-trifluoromethylpropionyl chloride as a pale yellow oil; k.p. 80-82°/16 mm. ;c) 1-[3-acetylthio)-2-trifluoromethyl-1-oxopropyl]-4-oxo-L-proline; D,L-3-(acetylthio)-2-trifluoromethylpropionyl chloride is reacted with 4-keto-L-proline -hydrobromide according to the method according to example .1 (d) to give 1-[(3-acetylthio)-2-trifluoromethyl-1-oxopropyl]-4-oxo-1-proline. This mixture of diastereoisomers can then be separated in the usual way. ;Example 6 ;1-(3-mercapto-2-trifluoromethyl-1-oxopropyl)-4-oxo-L-proline ;The product from example 5 (in the form of the diastereoisomeric mixture or as the separated isomers) is hydrolyzed with concentrated ammonia according to the method of Example 2 to give 1-(3-mercapto-2-trifluoromethyl-1-oxopropyl)-4-oxoj-L-proline. ;Example 7 ;( S)- 1-( 3- mercapto- 2- mercaptomethyl- l- oxopropyl)- 4- oxo- L- proline a) ( S)- l-[ 3-( acetylthio)- 2-( acetylthiomethyl )-1-oxopropyl]-4-oxo-L-proline. By following the procedure according to example 1, but using D-3-acetylthiomethyl-3-acetylthiopropionyl chloride instead of 3-acetylthiopropionyl chloride in part (d), (S)-1-[3-(acetylthio)-2-( acetylthiomethyl)-1-oxopropyl]-4-oxo-L-proline. ;b) (S)-1-(3-me.rcapto-2-mercaptomethyl-l-oxopropyl)-4-oxo-L-proline ;The product from part (a) is hydrolyzed with concentrated ammonia according to the method according to example 2 to give (S)-1-(3-mercap'to-2-mercaptom.ty 1-1-oxopropyl)-4-oxo-L-proline. ;Example 8 ;1-(3-mercapto-2-methylthio-l-oxopropyl)-4-oxo-L-proline;a) 3-(acetylthio)-2-(methylthio)propionic acid; 12.5 g (0.094 mol ) methyl 2-(methylthio)-acrylate [prepared from methyl 1-2-chloroacrylate according to the method of Gundesmann et al., Chemische Berichte 9_4, 3254 (1916)] is stirred with 1N aqueous sodium hydroxide (94 ml) with ice-cooling. The mixture is allowed to warm to ambient temperature and then stirred for 5 hours. It. the resulting solution is washed with ether and then acidified to pH 2 with concentrated hydrochloric acid. The solid precipitate is extracted into methylene chloride, and the solution is washed with saturated sodium chloride, and the solvent is evaporated. The solid residue, 2-(methylthio)-acrylic acid, m.p. 70-75°; is applied immediately in the following transaction. ;i ;Equimolar amounts of 2-(methylthio)acrylic acid and thiolacetic acid are mixed under argon and stirred at 80° for several hours to give 3-(acetylthio)-2-(methylthio)propionic acid. b) 3-(acetylthio)-2-(methylthio)propionic acid chloride 3-(acetylthio)-2-(methylthio)propionic acid is refluxed in thionyl chloride for 2 hours. The reaction mixture is distilled to remove excess thionyl chloride, and the product is distilled in vacuo to give 3-(acetylthio)-2-(methylthio)propionic acid chloride. ;c) 1-[ 3-(acetylthio)-2-methylthio-l-oxopropyl]-4-oxo-L-proline 3-(acetylthio)-2-(methylthio)propionic acid chloride is reacted with ;4-keto-L-proline -hydrobromide according to the method of Example 1 (d) to give 1-[3-(acetylthio)-2-methylthio-1-oxopropyl]-4-oxo-L-proline. ;d) 1-(3-mercapto-2-methylthio-l-oxopropyl)-4-oxo-L-proline The product from part (c) is hydrolyzed with concentrated ammonia according to the procedure according to example 2 to give 1-( 3-mercapto-2-methylthio-1-oxopropyl)-4-oxo-L-proline. ;Example 9;1-( 4-mercaptol-1-oxobutyl)-4-oxo-L-proline;a) ' 1-[ 4-(acetylthio)-1-oxobutyl]-4-oxo-L-proline; By to follow the procedure according to example 1, but by using 4-acetylthiobutyroyl chloride instead of 3-acetylthiopropionyl chloride in part (d), 1-[4-(acetylthio)-1-oxobutyl]-4-oxo-L-proline is obtained. ;b) 1-(4-mercaptol-l-oxobutyl)-4-oxo-L-proline ;The product from part (a) is hydrolyzed with concentrated ;ammonia according to the procedure according to example 2 to give 1-(4-mercapto -1-oxobutyl)-4-oxo-L-proline. ;Example 10;1-(2-mercaptol-l-oxoethyl)-4-oxo-L-proline;a) 1-[2-(acetylthio)-1-oxoethyl]-4-oxo-L-proline;By following the procedure according to example 1, but by using acetylthioacetyl chloride instead of 3-acetylthiopropionyl chloride in part (d), 1-[2-(acetylthio)-1-oxo-ethyl]-4-oxo-L-proline is obtained. ;b) 1-(2-mercaptol-ol-oxoethyl)-4-oxo-L-proline ;The product from part (a) is hydrolyzed with concentrated ammonia according to the procedure according to example 2 to give 1-(2-mercapto- 1-oxoethyl)-4-oxo-L-proline. ;Example 11 ;. 1-( 3- mercapto- 2, 2- dimethyl- l- oxopropyl)- 4- oxo- L- proline; a) 1-[ 3- ( acetylthio)- 2, 2- dimethyl- l- oxopropyl]- 4- oxo-L-proline By following the procedure according to example 1, but using 3-acetylthio-2,2-dimethylpropionyl chloride instead of 3-acetylthiopropionyl chloride in part (d), one obtains 1-[3-(acetylthio)-2, 2-dimethyl-1-oxopropyl]-4-oxo-L-proline. b) 1-(3-mercapto-2,2-dimethyl-l-oxopropyl)-4-oxo-L-proline The product from part (a) is hydrolyzed with concentrated ammonia according to the procedure of example 2, to give 1-(3-mercapto-2,2-dimethyl-1-oxopropyl)-4-oxo-L-proline. ;Example 12 ;( S)- 1-( 3- mercapto- 2- ethyl- l- oxopropyl)- 4- oxo- L- proline; a) ( S)- 1- [ 3- ( acetylthio)- 2- eth 1-1-oxopropyl]-4-oxo-L-pr'olin By following the procedure according to example 1, but using D-3-acetylthio-2-ethylpropionyl chloride instead of D-3-acetylthio-2-methylpropionyl chloride in part (d), (S)-1-[3-(acetylthio)-2-ethyl-1-oxopropyl]-4-oxo-L-proline is obtained. b) (S)-1-(3-mercapto-2-ethyl-1-oxopropyl)-4-oxo-L-proline; The product from part (a) is hydrolyzed with concentrated ammonia according to the procedure according to example 2 for to give (S)-1-(3-mercapto-2-ethyl-1-oxopropyl)-4-oxo-L-proline. ;Example 13;i ;1-( 3- mgrkapto-l- oxopropyl)- 4- oxo- L- pipecolic acid; a) 1-[ 3-( acetylthio)- 1- oxopropyl]- 4- oxo- L- pipecolic acid; i ; By following the procedure according to example 1,. but using 4-keto-L-pipecolic acid instead of 4-keto-L-proline in part (d), 1-[3-(acetylthio)-1-oxopropyl]-4-oxo-L-pipecolic acid is obtained. ;b) 1-(3-mercapto-l-oxopropyl)-4-oxo-L-pipecolic acid ;The product from part (a) is hydrolyzed with concentrated ;ammonia to give 1-(3-mercapto-l-oxopropyl)-4 -oxo-L-pipecolic acid. ; Example 14 ; ( S)- 1-( 3- mercapto- 2- methyl- l- oxopropyl)- 5- oxo- L- pipecolic acid; a) ( S.) - 1- [ 3 - ( acetylthio) - 2- methyl 1- 1-oxopropyl] - 5-oxo-L-pipecolic acid.r By following the procedure according to example 1, but using 5-keto-L-pipecolic acid instead of 4-keto-L-proline in part (d) and D-3-acetylthio-2-methylpropionyl chloride instead of acetylthiopropionyl chloride in part (d), one obtains (S)-1-[3-(acetylthio-2-methyl-1-oxopropyl]-5-keto-L-pipecolic acid. ;b ) ( S )- 1-( 3- mercapto- 2- methyl 1- 1- oxopropyl)- 5- keto- L-pipecolic acid The product from part (a) is hydrolyzed with concentrated ammonia according to the procedure of Example 2 to give ;( S)-1-(3-mercapto-2-methyl-1-oxopropyl)-5-keto-L-pipecolic acid. Example 15 1-(3-mercapto-2-trifluoromethyl-1-oxopropyl)-4-oxo-L-proline;a) 3-[[(4-methoxy)phenylmethyl]thio]-2-trifluoromethylpropiony1-k chloride ;An undiluted mixture of 1-trifluoromethylacrylic acid (3.9 g) and 4-methoxybenzylthiol (4.3 g) is stirred at 100-110° for 1 hour. The mixture is allowed to cool to room temperature and the solid is recrystallized from cyclohexane to give 3-[[(4-methoxy)phenylmethyl]thio]-2-trifluoromethylpropionic acid, m.p. 72-74°. Treatment of this acid with thionyl chloride gives 3-[[(4-methoxy)phenylmethyl]thio]-2-trifluoromethylpropionyl chloride. ;b) 1"^ [ 3 — [ [ ( 4- methoxy) phenylmethyl] thio] - 2- trifluoromethyl- l- oxopropyl]- 4- oxo- L- proline ; 3-[[(4- methoxy) phenylmethyl] thio The ]-2-trifluoromethylpropionyl chloride from part (a) is reacted with 4-keto-L-proline to give 1-[3-[[(4-methoxy)phenylmethyl]thio]-2-trifluoromethyl-1-oxopropyl ]-4-oxo-L-proline.;c) 1-(3-mercapto-2-trifluoromethyl-1-oxopropyl)-4-oxo-L-proline The product from part (b) is mixed with trifluoroacetic acid and ;anisole under nitrogen. The solvents are removed under vacuum to give as a residue 1-(3-mercapto~2-trifluoromethyl-1-oxopropyl)-4-oxo-L-proline. ;Example 16 ;( S)- 1-( 3-mercapto- 3- methyl- l- oxopropyl)- 4- oxo- L- proline; a) (S)- 1-[ 3-( acetylthio)- 3- methyl- l- oxopropyl]- 4- oxo- L- proline f By to follow the procedure according to example 1, but by using D-3-acetylthio-3-methylpropionyl chloride instead of 3-acetylthiopropionyl chloride in part (d), one obtains (S)-1-[3-(acetylthio)-3-methyl- 1-oxopropyl]-4-oxo-L-proline.;b) (S)-1-(3-mercapto-3-methyl1-1 - oxopropyl)- 4-oxo-L-proline The product from part (a) is hydrolyzed with concentrated ammonia to give (S)-1-(3-mercapto-3-methyl-1-oxopropyl)-4-oxo-L -proline. ;Examples 17-25;By following the procedure according to example 1, but by using the acid chloride indicated below in column I instead of 3-acetylthiopropionyl chloride, the acyl mercapto product indicated below in column II is obtained. ; Example 26: (S)-1-(3-mercapto-2-methyl.1-1-oxopropyl)-4-oxo-L-proline-1-adamantanamine salt; The product according to example 4 can also be prepared according to the following procedure. ;a) N-carbobenzyloxy-4, 4-dime toxy-L-proline- methyl ester; A stirred solution of 7.8 g. (0.03 mol) N-carbobenzyloxy-4-keto-L-proline from example 1 in 60 ml of methanol is treated with 96 ml of trimethylorthoformate, followed by 0.6 ml of concentrated sulfuric acid, and allowed to stand at room temperature overnight. The pale yellow solution is stirred, treated with 1.5 g of potassium carbonate, followed by 30 ml of water, and most of the solvent is removed on a rotary evaporator to give a syrupy residue which is shaken with 30 ml of water and 30 ml of chloroform. After separation of the layers, the aqueous phase is extracted with further chloroform (3 x 30 ml), and the combined organic layers are washed with 45 ml of saturated sodium chloride solution and dried (MgSO 4 ). Evaporation of the solvent gives 8.4 g (88%) of N-carbobenzyloxy-4,4-dimethoxy-L-proline methyl ester. ;b) N- carbobenzyloxy- 4, 4- dimethoxy- L- proline; The ester (8.4 g, 0.026 mol) from part (a) is dissolved in 80 ml of ; methanol, treated dropwise at -1° to 4° with 18 .ml (0.036 mol) of 2N sodium hydroxide, keeping it at 0° for 1 hour, and at room temperature overnight. After removing approx. half of the solvent on a rotary evaporator, the solution is diluted with 150 ml of water, washed with 100 ml of ether (washing liquids are discarded), acidified while cooling with 63 ml of 1:1 hydrochloric acid to pH 2, and extracted with ethyl acetate (4 x 750 ml) . The combined extracts are washed with 50 ml saturated sodium chloride solution, dried (MgSO 4 ), and the solvent evaporated to give 8.0 g of a pale yellow viscous oil. The oil is dissolved in 35 ml of ethanol, treated with 3.0 g of cyclohexylamine in 10 ml of ethanol and diluted to 500 ml with ether. During inoculation and rubbing, the crystalline N-carbobenzyloxy-4,4-dimethoxy-L-proline-cyclohexylamine salt is secreted; weight after cooling overnight, 7.0 g, m.p. 157-159° (p. 151) [«]^<6>-34° (c, 1% in EtOH). This material is recrystallized from 100 mL of acetonitrile to give the salt as a colorless solid, m.p. 158-160° (p. 154°), [a]^<6>-33° (c, 1% in EtOH). The N-carbobenzyloxy-4,4-dimethoxy-L-proline-cyclohexylamine salt is suspended in 40 ml of ethyl acetate, stirred and treated with 25 ml of IN hydrochloric acid. When two clear layers are obtained, they are separated, in which the aqueous phase is extracted with further ethyl acetate (3 x 40 ml), the combined organic layers are dried (MgSO 4 ), and the solvent is evaporated, finally at 0.2 mm and 40 ° to give 7.2 g (70%) of N-carbobenzyloxy-4,4-dimethoxy-L-proline as a pale yellow viscous syrup. ;c) 4, 4-dimethoxy-L-proline; A solution of N-carbobenzyloxy-4,4-dimethoxy-L-proline (72 g, '0.022.11101) in 210 ml methanol-water (2:1) is treated with 2.3 g 5% palladium charcoal and shaken on a Parr hydrogenation apparatus for 6 hours. The catalyst is filtered off under nitrogen, washed with methanol, and the combined filtrates are evaporated, finally at 0.1-0.2 mm to give a partially crystalline residue. This residue is taken up in 200 ml of methanol, and the evaporation is repeated. When the solid is rubbed under ether (evaporation is repeated again), 3.6 g (95%) of almost colorless 4,4-dimethoxy-L-proline are obtained, m.p. 192-194° (dec.); [α]^<6>-47° (c, 1% in MeOH). ;A sample recrystallized from methanol-ether is colorless and melts at 19.7-198° (dec.); [α]^ 6 -49° (c, 1% in MeOH). ;d) ( S )- 1-[ 3-( acetylthio )- 2- methyl 1- 1- oxopropyl]- 4, 4- dimethoxy-L- proline ; A stirred solution of 3.3 g (0.019 mol) 4.4 -dimethoxy-L-proline in 50 ml of water is cooled to 5° and brought to pH 8.5 by adding 25% sodium carbonate solution (weight/volume). With continued stirring and cooling, a solution of 3.8 g (0.021 mol) of D-3-acetylthio-2-methylpropanoyl chloride in 5 ml of ether is added portionwise while the pH value is maintained at 7.5-8.5 by the dropwise addition of 25 % sodium carbonate solution. When the pH value has stabilized at 8.2-8.4 (after about 15 minutes), stirring and cooling are continued for a total of 1 hour. The solution is then washed with 50 ml of ethyl acetate (washes are discarded) covered with 50 ml of ethyl acetate, cool, stir, acidify carefully with ;1:1 hydrochloric acid to pH 2.0, saturate with sodium chloride, and separate the layers. The aqueous phase is extracted with further ethyl acetate (3 x 50 ml), the combined organic layers are dried ( MgSO^), and the solvent is evaporated, finally at 0.2 mm, to give 6.7 g of syrupy product. This syrup is treated in 70 ml of ethyl acetate with 3.9 g of dicyclohexylamine to give 6.5 g of colorless (S )-1-[3-(acetylthio)-2-methyl-1-oxopropyl]-4,4-dimethoxy-L-proline-dicyclohexylamine salt in two portions (3.1 g and 3.4 g), m.p. 15 8-160° (p. 145°), [2.]^<6>-71° (c, 1% in EtOH).. ;After recrystallization from 20 ml of hot ethyl acetate - 60 ml of hexane, the colorless solid salt weighs 6.0 g, sm. p. 158-166° (s, 155°), [α]^<5>-69° (c, 1% in EtOH). The dicyclohexylamine salt is converted to the free acid by suspending 5.0 g in 50 ml of ethyl acetate, cooling and treating with 60 ml of 10% potassium bisulphate solution to give two clear layers. After drying, the aqueous phase is extracted with ethyl acetate (3 x 50 ml), the combined organic layers are dried (MgSO4), and the solvent is evaporated, finally at 0.1'-0.2 mm and 45° to give 4 .1 g (69%) (S)-1-[3-(acetylthio)-2-methyl-1-oxopropyl]-4,4-dimethoxy-L-proline as a viscous, almost glass-like material, [a]^ -112° (c, 1% in EtOH). ;e) (S)- 1-(3-mercapto-2-methyl-l-oxopropyl)-4, 4- dimethoxy-L-proline ;Argon is passed through a cold solution of 8.5 ml of concentrated ammonium hydroxide in 20 ml of water for 0.25 hours. The latter is then added under cooling and under a blanket of argon to 4.1 g (0.013 mol) (S)-1-[3-(acetylthio)-2-methyl-1-oxopropyl]-4,4-dimethoxy-L -proline, and the mixture is kept moving in an ice bath until a pale yellow solution is obtained (approx. 15 minutes). Stirring under argon is continued at room temperature for a further 2 hours, then the solution is extracted with 30 ml of ethyl acetate (this and subsequent operations are carried out to the greatest extent possible under an argon atmosphere). ;The aqueous layer is cooled, stirred, covered with 30 ml. ethyl acetate and acidified in portions with approx. 16 ml of 1:1 hydrochloric acid. The layers are separated, the aqueous phase is extracted with additional ethyl acetate (3 x 30 ml), the combined ethyl acetate layers are dried (MgSO 4 ), and the solvent is evaporated to give 3.5 g (100%) ;( S)-1-(3-mercapto-2-methyl-1-oxopropyl)-4,4-dimethoxy-L-proline as a colorless, viscous syrup, [<*]^ -72° (c, 1% in EtOH ).
Sistnevnte (3,4 g) utgnies med 20 ml etylacetat, gnies, fortynnes med 30 ml heksan, og avkjøles for å gi et farveløst, fast stoff, vekt 2,6 g, sm.p. 10C-110°, [ct]^<5>-77° (c, 1% i EtOH). The latter (3.4 g) is triturated with 20 ml of ethyl acetate, triturated, diluted with 30 ml of hexane, and cooled to give a colorless solid, weight 2.6 g, m.p. 10C-110°, [ct]^<5>-77° (c, 1% in EtOH).
f) ( S)- 1-( 3- merkapto- 2- metyl- l- oksopropyl)- 4- okso- L- prolin-1- adamantanaminsalt-(S)-1-(3-merkapto-2-metyl-l-oksopropyl)-4,4-dimetoksy-L-prolin (0,4 g, 0,0014 mol) settes til 8 ml omrørt.N HC1 gjennom hvilken det på forhånd er ført argon i 10 minutter. Efter at man har fått en oppløsning, lukkes kolben under argon og holdes natten over ved romtemperatur. De følgende trinn foretas også under en argonatmosfære i størst mulig utstrekning. Til den omrørte oppløsning settes 20 ml metylenklorid, og efter f) (S)-1-(3-mercapto-2-methyl-1-oxopropyl)-4-oxo-L-proline-1-adamantanamine salt-(S)-1-(3-mercapto-2-methyl-1) -oxopropyl)-4,4-dimethoxy-L-proline (0.4 g, 0.0014 mol) is added to 8 ml of stirred N HCl through which argon has previously been passed for 10 minutes. After a solution has been obtained, the flask is closed under argon and kept overnight at room temperature. The following steps are also carried out under an argon atmosphere to the greatest extent possible. Add 20 ml of methylene chloride to the stirred solution, and then
metning med natriumklorid adskilles lagene. Den vandige(fase ekstraheres med ytterligere metylenklorid (3 x 15 ml), de saturation with sodium chloride separates the layers. The aqueous phase is extracted with further methylene chloride (3 x 15 ml), de
organiske lag samles, tørres (MgSO^), og oppløsningsmidlene avdampes for å gi et skumaktig residuum. Efter utgnidning med organic layers are collected, dried (MgSO 4 ), and the solvents evaporated to give a foamy residue. After rubbing with
eter (inndampning gjentas), får man 0,26 g (S)-1-(3-merkapto- . 2-metyl-l-oksopropyl)-4-okso-L-prolin som et amorft, fast stoff (hygroskopisk). ether (evaporation is repeated), 0.26 g of (S)-1-(3-mercapto-.2-methyl-1-oxopropyl)-4-oxo-L-proline is obtained as an amorphous solid (hygroscopic).
0,245 g av dette produkt oppløses i 7 ml acetonitril og behandles med 0,17 g 1-adamantanamin for å- utfelle saltet som et voluminøst, fast stoff. Efter avkjøling natten over filtreres det farveløse materiale, vaskes med kald acetonitril og eter, og tørres i vakuum for å gi 0,36 g (S)-1-(3-merkapto-2-metyl-l-oksopropyl)-4-okso-L-prolin-l-adamantanaminsalt (1:1), sm.p. 188-190° (dek.), s. 184°, [ a]^ 5 - 13° (c, 1% i metanol). 0.245 g of this product is dissolved in 7 ml of acetonitrile and treated with 0.17 g of 1-adamantanamine to precipitate the salt as a voluminous solid. After cooling overnight, the colorless material is filtered, washed with cold acetonitrile and ether, and dried in vacuo to give 0.36 g of (S)-1-(3-mercapto-2-methyl-1-oxopropyl)-4-oxo -L-proline-l-adamantanamine salt (1:1), m.p. 188-190° (dec.), p. 184°, [ a]^ 5 - 13° (c, 1% in methanol).
Analyse:Analysis:
Beregnet for CgH^NO^S-C^H^N-0, 25H20:Calculated for CgH^NO^S-C^H^N-0, 25H20:
C 58,96, H 8,02, N 7,24, S 8,29, C 58.96, H 8.02, N 7.24, S 8.29,
Funnet: C 58,60, H 8,37, N 7,16, S 8,29. Found: C 58.60, H 8.37, N 7.16, S 8.29.
Eksempel 2 7 Example 2 7
1, 1'-[ ditiobis( l- okso- 3, 1- propandiyl)] bis[ 4- okso- L- prolin] 1, 1'-[dithiobis(l-oxo-3,1-propanediyl)]bis[4-oxo-L-proline]
Produktet fra eksempel 2 oppløses i vann, og pH reguleres til 6,5 ved tilsetning av IN natriumhydroksyd. Til denne om-rørte,oppløsning settes dråpevis en 0,5M jodoppløsning i 95% etanol (6,34 g jod/50 ml oppløsning) mens pH-verdien. holdes ved 5,5 til 6,5 med IN natriumhydroksyd. Overskudd av jod fjernes med fortynnet natriumtiosulfat, og oppløsningén konsentreres, avkjøles og surgjøres med 1:1 saltsyre. Opp- • løsningsmiddel tilsettes, og lagene adskilles.. Det organiske lag tørres (MgSO^) og oppløsningsmidlet avdampes for å gi som residuum 1,1' - [ditiobis (1-okso -3 ,1-propandiyl) ] bis'[ 4-okso-L-prolin].. The product from example 2 is dissolved in water, and the pH is adjusted to 6.5 by adding IN sodium hydroxide. A 0.5 M iodine solution in 95% ethanol (6.34 g iodine/50 ml solution) is added dropwise to this stirred solution, while the pH value. maintained at 5.5 to 6.5 with IN sodium hydroxide. Excess iodine is removed with dilute sodium thiosulphate, and the solution is concentrated, cooled and acidified with 1:1 hydrochloric acid. Solvent is added, and the layers are separated. The organic layer is dried (MgSO4) and the solvent is evaporated to give as a residue 1,1'-[dithiobis(1-oxo-3,1-propanediyl)] bis'[ 4 -oxo-L-proline]..
Eksempel 2 8 Example 2 8
1-[ 3-( acetyltio)- 1- oksopropy1]- 4- okso- L- prolin- metylester1-[ 3-( acetylthio)- 1- oxopropyl]- 4- oxo- L- proline- methyl ester
En oppløsning av produktet fra eksempel 1 i eter beh'andles med et lite overskudd av diazometan. Efter henstand ved romtemperatur i 2 timer avdampes oppløsningsmidlet for å gi 1-[3-(acetyltio)-1-oksopropyl]-4-okso-L-prolin-metylester. A solution of the product from example 1 in ether is treated with a small excess of diazomethane. After standing at room temperature for 2 hours, the solvent is evaporated to give 1-[3-(acetylthio)-1-oxopropyl]-4-oxo-L-proline methyl ester.
Eksempel 29 Example 29
1-( 3- merkapto- l- oksopropyl)- 4- okso- L- prolin- metylester1-(3-mercaptol-l-oxopropyl)-4-oxo-L-proline methyl ester
Produktet fra eksempel 2 8 hydrolyseres med konsentrert ammoniakk i henhold til fremgangsmåten ifølge eksempel 2 for å gi 1-(3-merkapto-l-oksopropy1)-4-okso-L-prolin-metylester. The product from Example 2 8 is hydrolyzed with concentrated ammonia according to the method of Example 2 to give 1-(3-mercapto-1-oxopropyl)-4-oxo-L-proline methyl ester.
Eksempel 30 Example 30
1-( 3- merkapto- l- oksopropyl)- 4- okso- L- prolin- natriumsalt 1-(3-mercaptol-l-oxopropyl)-4-oxo-L-proline sodium salt
En oppløsning av 1,0 g av produktet ifølge eksempel 2 oppløses i 10 ml vann og behandles med en ekvivalent natrium-bikarbonat. Oppløsningen frysetørres for å gi 1-(3-merkapto-1-oksopropyl)-4-okso-L-prolin-natriumsalt. A solution of 1.0 g of the product according to example 2 is dissolved in 10 ml of water and treated with an equivalent of sodium bicarbonate. The solution is lyophilized to give 1-(3-mercapto-1-oxopropyl)-4-oxo-L-proline sodium salt.
Ved å anvende kaliumbikarbonat får man på lignende måteUsing potassium bicarbonate is obtained in a similar way
det tilsvarende kaliumsalt. ■ the corresponding potassium salt. ■
Eksempel 31 • Example 31 •
( S) - 1- ( 3- merkapto- 2- mety 1- 1- oksopropyl) - 4- ok' so- L- prolin-natriumsalt ( S) - 1- ( 3- mercapto- 2- methyl 1- 1- oxopropyl) - 4- ok' so- L- proline sodium salt
En oppløsning av 1,0 g av produktet ifølge eksempel 4 oppløses i 10 ml vann og behandles med en ekvivalent natrium-bikarbonat. Oppløsningen frysetørres for å gi 1-(3-merkapto-2-metyl-l-oksopropyl)-4-okso-L-prolin-natriumsalt. A solution of 1.0 g of the product according to example 4 is dissolved in 10 ml of water and treated with an equivalent of sodium bicarbonate. The solution is lyophilized to give 1-(3-mercapto-2-methyl-1-oxopropyl)-4-oxo-L-proline sodium salt.
På lignende måte, under anvendelse av kaliumbikarbonat, får man det tilsvarende kaliumsalt. In a similar way, using potassium bicarbonate, the corresponding potassium salt is obtained.
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NO800620A NO800620L (en) | 1980-03-04 | 1980-03-04 | PROCEDURE FOR THE PREPARATION OF PROLINIC AND PIPE CARBIC ACID DERIVATIVES. |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NO800620A NO800620L (en) | 1980-03-04 | 1980-03-04 | PROCEDURE FOR THE PREPARATION OF PROLINIC AND PIPE CARBIC ACID DERIVATIVES. |
Publications (1)
Publication Number | Publication Date |
---|---|
NO800620L true NO800620L (en) | 1981-09-07 |
Family
ID=19885365
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO800620A NO800620L (en) | 1980-03-04 | 1980-03-04 | PROCEDURE FOR THE PREPARATION OF PROLINIC AND PIPE CARBIC ACID DERIVATIVES. |
Country Status (1)
Country | Link |
---|---|
NO (1) | NO800620L (en) |
-
1980
- 1980-03-04 NO NO800620A patent/NO800620L/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4296113A (en) | Mercaptoacyl derivatives of keto substituted proline and pipecolic acid | |
US4310461A (en) | Imido, amido and amino derivatives of mercaptoacyl prolines and pipecolic acids | |
US4390695A (en) | Imido, amido and amino derivatives of mercaptoacyl prolines and pipecolic acids | |
US4154935A (en) | Halogen substituted mercaptoacylamino acids | |
US4578474A (en) | Imido, amido and amino derivatives of mercaptoacyl prolines and pipecolic acids | |
US4192945A (en) | Process for preparing proline and homoproline derivatives | |
CA1168245A (en) | Carboxyalkanoyl and hydroxycarbamoylalkanoyl derivatives of substituted prolines | |
CS228118B2 (en) | Production of mercaptoacylderivatives of substitutes prolines | |
NO153569B (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE BRAND CAPACETYL-PROLIN DERIVATIVES. | |
JPS604815B2 (en) | proline derivative | |
US4296033A (en) | 4-Azido-1-mercaptoacyl proline | |
US3976660A (en) | Pyrrolidine derivatives | |
US4241076A (en) | Halogenated substituted mercaptoacylamino acids | |
NO790568L (en) | PROCEDURE FOR THE PREPARATION OF HALOGEN-SUBSTITUTED MARKAPTOACYLAMINO ACIDS | |
NO155240B (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE AROYL (PROPIONYL OR BUTYRYL) -L-PROLINE DERIVATIVES. | |
CA1124726A (en) | Derivatives of pyrrolidinecarboxaldehyde and piperidinecarboxaldehyde and intermediates therefor | |
EP0095584B1 (en) | Substituted 4-phenoxy and 4-phenylthio prolines | |
NO800620L (en) | PROCEDURE FOR THE PREPARATION OF PROLINIC AND PIPE CARBIC ACID DERIVATIVES. | |
EP0042639B1 (en) | Azido, imido, amido and amino derivatives of mercaptoacyl prolines and pipecolic acids having hypotensive activity | |
US4330548A (en) | Mercaptoacyl derivatives of keto substituted pipecolic acid | |
US4456761A (en) | 4-Substituted dehydroprolines | |
CA1138878A (en) | Mercaptoacyl derivatives of keto substituted proline and pipecolic acid | |
SE431331B (en) | NEW THERAPEUTICALLY ACTIVE SULFUR CONTAINING N-ACYLATED DERIVATIVES OF 4-OXO-L-PROLINE | |
US4499287A (en) | Certain-4-hydroxy-proline derivatives | |
US4308388A (en) | 4-Azido-1-mercaptoacyl pipecolic acid |